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Machine Learning Methods in Personalized Medicine
Using Electronic Health Records
Peng Wu
The theme of this dissertation focuses on methods for estimating personalized treatment using
machine learning algorithms leveraging information from electronic health records (EHRs). Cur-
rent guidelines for medical decision making largely rely on data from randomized controlled trials
(RCTs) studying average treatment effects. However, RCTs are usually conducted under specific
inclusion/exclusion criteria, they may be inadequate to make individualized treatment decisions
in real-world settings. Large-scale EHR provides opportunities to fulfill the goals of personalized
medicine and learn individualized treatment rules (ITRs) depending on patient-specific character-
istics from real-world patient data. On the other hand, since patients’ electronic health records
(EHRs) document treatment prescriptions in the real world, transferring information in EHRs to
RCTs, if done appropriately, could potentially improve the performance of ITRs, in terms of pre-
cision and generalizability. Furthermore, EHR data domain usually consists text notes or similar
structures, thus topic modeling techniques can be adapted to engineer features.
In the first part of this work, we address challenges with EHRs and propose a machine learning
approach based on matching techniques (referred as M-learning) to estimate optimal ITRs from
EHRs. This new learning method performs matching method instead of inverse probability weight-
ing as commonly used in many existing methods for estimating ITRs to more accurately assess
individuals’ treatment responses to alternative treatments and alleviate confounding. Matching-
based value functions are proposed to compare matched pairs under a unified framework, where
various types of outcomes for measuring treatment response (including continuous, ordinal, and dis-
crete outcomes) can easily be accommodated. We establish the Fisher consistency and convergence
rate of M-learning. Through extensive simulation studies, we show that M-learning outperforms
existing methods when propensity scores are misspecified or when unmeasured confounders are
present in certain scenarios. In the end of this part, we apply M-learning to estimate optimal
personalized second-line treatments for type 2 diabetes patients to achieve better glycemic control
or reduce major complications using EHRs from New York Presbyterian Hospital (NYPH).
In the second part, we propose a new domain adaptation method to learn ITRs in by incorpo-
rating information from EHRs. Unless assuming no unmeasured confounding in EHRs, we cannot
directly learn the optimal ITR from the combined EHR and RCT data. Instead, we first pre-train
“super” features from EHRs that summarize physicians’ treatment decisions and patients’ observed
benefits in the real world, which are likely to be informative of the optimal ITRs. We then augment
the feature space of the RCT and learn the optimal ITRs stratifying by these features using RCT
patients only. We adopt Q-learning and a modified matched-learning algorithm for estimation. We
present theoretical justifications and conduct simulation studies to demonstrate the performance of
our proposed method. Finally, we apply our method to transfer information learned from EHRs of
type 2 diabetes (T2D) patients to improve learning individualized insulin therapies from an RCT.
In the last part of this work, we report M-learning proposed in the first part to learn ITRs using
interpretable features extracted from EHR documentation of medications and ICD diagnoses codes.
We use a latent Dirichlet allocation (LDA) model to extract latent topics and weights as features
for learning ITRs. Our method achieves confounding reduction in observational studies through
matching treated and untreated individuals and improves treatment optimization by augmenting
feature space with clinically meaningful LDA-based features. We apply the method to extract
LDA-based features in EHR data collected at NYPH clinical data warehouse in studying optimal
second-line treatment for T2D patients. We use cross validation to show that ITRs outperforms
uniform treatment strategies (i.e., assigning insulin or another class of oral organic compounds to
all individuals), and including topic modeling features leads to more reduction of post-treatment
complications.
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CHAPTER 1. BACKGROUND AND OVERVIEW 1
Chapter 1
Background and Overview
Medical research is increasingly focusing on personalized treatment for an individual patient, which
will gradually replace “one-size-fits-all” strategy in traditional medical practice. This transition is
partially fueled by the recent advances in modern technologies that provide medical professionals
and researchers with large-scale personal data (e.g. clinical measurements, biomarkers, pre-existing
or developing conditions available in electronic health records). Selection of treatment strategy can
be tailored towards each individual patient according to their person-specific characteristics, which
is an important and beneficial move towards personalization of medical practice. The primary goal
in this work is to merge statistical modeling techniques with machine learning algorithms to discover
optimal individualized treatment rules (ITRs) applicable to various study designs and primary
outcomes, including randomized experiments and observational studies with continuous or discrete
outcomes. We will review how to achieve the goal of personalized medicine by assigning optimized
ITRs to individual patients, existing methods for estimating ITRs, and introduce matching and
propensity score based methods for observational studies. In addition, we will discuss critical
issues of statistical analysis of electronic health records (EHRs), and demonstrate the utility of
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our methods through case studies of a real world RCT data and EHRs extracted from New York
Presbyterian Hospital (NYPH) and Columbia University Medical Center (CUMC). Lastly we will
discuss topic modeling techniques in extracting latent topics in EHR data and engineering features.
1.1 Personalized Medicine and Individualized Treatment Rule
Personalized medicine calls for a paradigm shift from the universal strategy that assigns the same
treatment to all patients affected by a disorder to selecting treatment strategies that optimize in-
dividual patient’s health outcomes according to individual characteristics (Hamburg and Collins,
2010; Collins and Varmus, 2015). Improvements in technologies for collecting personal data, accom-
panied with developments of machine learning and statistical methods to analyze these data, hold
promise to enable healthcare providers to prescribe the right therapy to the right patient at the
right time (Collins and Varmus, 2015; Chakraborty and Moodie, 2013). By treating each patient
with the optimal individualized treatment, patients can potentially gain enhanced clinical benefits,
experience less side effects, and be more adherent to treatments (Chakraborty and Moodie, 2013).
It is of interest to learn effective individualized treatment rules (ITRs) to reflect real world evidence
using data collected in practical clinical settings (e.g., electronic health records, EHRs).
1.2 Q-learning and O-learning Methods
Over the past decade, a body of literature on how to accurately and efficiently estimate optimal
individualized medical treatment using semiparametric methods and machine learning methods is
growing in popularity (Murphy et al., 2007; Lavori and Dawson, 2004; Chakraborty and Moodie,
2013). Previously proposed machine learning approaches including Q-learning (Qian and Murphy,
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2011), Outcome-weighted learning (O-learning) (Zhao et al., 2012) and augmented O-learning (Liu
et al., 2018) provide valuable tools to effectively estimate simple and informative ITRs.
Q-learning was first proposed by Watkins (1989) as a form of reinforcement learning, in which
“Q” represents “quality of action” (Watkins and Dayan, 1992; Watkins, 1989). Murphy, Qian et
al. (2007, 2011) (Murphy et al., 2007; Qian and Murphy, 2011) implemented regression-based Q-
learning to determine optimal ITR in each stage of a sequential multiple assignment randomized
trials (SMARTs). The Q-function related to clinical outcomes is first approximated by a regression
model and then maximized in each stage to select the optimal ITR. The ITR estimated using
this regression-based approach may be sensitive to incorrect model assumptions in the estimation
process, especially in high-dimensional feature space setting. Zhang et al. (2012) (Zhang et al., 2012)
proposed an alternative approach referred as augmented inverse probability weighting (AIPW) to
alleviate model misspecification and improve robustness. The method involves propensity score
estimation which will be reviewed in the next section.
1.3 Methods for Observational Studies
Several methods discussed in the previous section mainly focus on randomized experiments. For
observational studies, since treatments are not assigned randomly, without proper adjustments one
cannot estimate an ITR with causal interpretation. Common practice to adjust for confounding
due to observed covariates in the context of ITR estimation includes inverse probability weighting
by propensity scores (i.e., the conditional probability of being assigned to a treatment given a
subject’s baseline covariates (Rosenbaum and Rubin, 1983)) or with additional augmentation in
double robust estimation (Zhang et al., 2012, 2013). There are several potential limitations with
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inverse probability weighted approaches. First, the approach requires a sophisticated model for
estimating the propensity scores which often depends on some parametric and semiparametric
models, and therefore subject to model misspecification; even if machine learning approach is used
for this estimation such as classification and regression trees (CART), results can be sensitive
to extreme weights and high variability of weights (Lee et al., 2010, 2011; Austin and Stuart,
2015). For example, the weights for observations with a very low propensity of being assigned to
a particular observed treatment might be very unstable (Austin, 2011).Thus sensitivity analysis
related to influential observations is recommended in the context of IPW approaches (Ellis et al.,
2013). Second, it has been empirically observed that estimation of ITRs may be numerically
unstable when treatment assignment is not balanced within some subgroups (Liu et al., 2018).
Third, when the distribution of propensity scores have poor overlap between treatment arms, the
inverse weighting approaches may perform inadequately due to imprecise propensity estimates and
thus sensitive to misspecification (Crump et al., 2009).
Instead, a more robust and practically useful approach is based on matching. Matching has been
shown to be a simple and effective adjustment in various empirical studies especially when model
assumptions such as linearity is not be satisfied (Stuart and Green, 2008). Stuart (2010)(Stuart,
2010) provided a comprehensive review of matching methods for causal inference. In particular, they
reviewed nearest neighborhood matching, subclassification, and full matching. Each of these meth-
ods has their own advantage in different practical applications. For example, ratio matching using
nearest neighbor can ensure multiple good matching individuals from control group (or comparison
treatment group) for an individual treated subject, especially when one treatment assignment is
rare (Smith, 1997). Nearest neighbor matching with replacement is useful when treatment assign-
ment is imbalanced and matching with replacement can reduce bias and avoid the order issue in
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matching the treated units (Stuart, 2010; Dehejia and Wahba, 1999). Full matching, which can be
considered as a complicated form of subclassification, has beneficial effects in optimizing average
similarity between treated and control subjects within each matching set and makes good use of as
many observations as possible (Stuart, 2010; Hansen, 2004; Stuart and Green, 2008).
In addition, propensity scores can also be incorporated to adjust for confounding in observational
studies through matching or combination of weighting, matching and regression, and hence enable
less model-dependent causal inference (Imai and Ratkovic, 2014; Ho et al., 2007). (Antonelli et al.,
2018) proposed a doubly robust matching method by matching on both the propensity score and
the prognostic score (Hansen, 2008) which is defined as the expected outcome for a subject under
control treatment given his or her feature variables. They showed double robustness of this method,
especially when dealing with confounding issues in high-dimensional feature space setting (Antonelli
et al., 2018). Stuart et al. provided several guidance about matching methods for practical use: (1)
one key issue is to determine whether a certain set of features included for matching is appropriate
according to ignorability assumption; (2) similarity measure plays a crucial role in matching and one
can choose similarity measure best suited for a particular application. For instance, Mahalanobis
distance or exact matching within propensity score calipers could be utilized to achieve close balance
on a small set of features (Stuart, 2010), and many data-driven similarity measures have been
proposed to accommodate categorical or ordinal feature variables (Boriah et al., 2008).
Compared to IPW-based methods which rely on whether or not the propensity score is pre-
cisely and accurately estimated (Austin, 2011; Rubin, 2004), matching-based methods require less
model specification and can be nonparametric (Ho et al., 2007). IPW-based methods ensure differ-
ent treatment groups have similar distribution of confounders at the population level, while some
matching methods ensure balanced distribution at subgroup level and provide more flexible tools to
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control the quality of matching important confounders in subgroups or even on individual subjects.
For example, covariates selection, distance metric and measure of covariates balance can be com-
bined to optimize matching (Sekhon and Grieve, 2012). Since our goal is to achieve personalized
medicine and identify optimal ITRs for subjects with a given set of feature variables, exploring
matching methods to balance subgroup-level distributions is more desirable.
In conclusion, matching methods are important tools to achieve covariates balance and adjust-
ing for confounding in observational studies and holds advantages compared to inverse probability
weighting methods in various applications (Stuart, 2010; Rubin, 2004; Austin, 2011; Ho et al.,
2007). For instance, one can identify matching subjects to guarantee numerical stability, especially
when some subgroup rarely experience one particular treatment. All existing methods for estimat-
ing optimal ITR using observational studies involve various forms of inverse probability weighting,
and none leverages the advantage of matching. In this dissertation, we will develop novel methods
for ITR estimation that make use of the flexible and power general framework of matching appli-
cable to both randomized experiment and observational studies. Matched learning may perform
better especially when the treatment assignment is not balanced in some subgroups of RCT or in
observational studies where researchers do not have control over treatment assignment mechanism.
1.4 Case Study: Electronic Health Records (EHR)
In recent years, the use of EHR is continuously growing among clinical researchers with access to
large-scale clinical data warehouses and databases (Weiskopf and Weng, 2013; Weiskopf et al., 2013).
EHR data resources contain massive information which may allow researchers to answer clinical
questions at the subject-level, including the estimation of ITRs (Wang et al., 2016). Notwithstand-
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ing EHR providing massive valuable healthcare information on large patient population, addressing
research problems relying on EHR might face potential challenges since EHR data is not collected
for research oriented studies in the first place, but primarily for billing or other clinical purposes
(Haneuse and Daniels, 2016).
Hripcsak and Albers (2013) summarized several critical issues in clinical research using EHR
data: completeness, accuracy, complexity, and bias (Hripcsak and Albers, 2013). In EHR, missing
data is commonly seen and patients with sufficient complete clinical information may comprise
only a small portion. The incompleteness in EHR data is typically related to selection bias in
healthcare practice, which can be casted as a missing data problem. In order to properly address
the issue, assumptions on the missing data mechanism or selection process should be taken careful
consideration (Haneuse and Daniels, 2016; Little and Rubin, 2014). One simple method to handle
missing data is to run “complete case analysis” by omitting the records with missing information,
which requires strong assumption coined as missing completely at random (MCAR)(Little and
Rubin, 2014) that often does not hold for EHR data. In EHR context, some variables might provide
partial information on the missingness of the others, that is to say, using imputation to handle
missingness is valid under the assumption of missing at random (MAR) (Wells et al., 2013; Rubin
et al., 1995). Accuracy is another important issue for EHR research since EHR is almost never error
free due to complexities in electronic-based data collection, integration and management process
(Hogan and Wagner, 1997). Furthermore, complicated hierarchies of EHR data and temporal
attributes carry different levels of uncertainty which might require both medical domain knowledge
and statistical insights to better characterize patient information in EHR (Hripcsak and Albers,
2013; Tao et al., 2011). In contrast to selection bias, confounding bias has drawn extensive attention
in literature (Pearl, 2009; Bareinboim and Pearl, 2016). The non-experimental feature of EHR data
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collection brings major difficulties to making inferences and drawing valid conclusions (Wang et al.,
2016; Hripcsak et al., 2011). As mentioned in previous section, methods on propensity scores,
subclassification, and matching are emerging to deal with various biases in EHR (Haneuse and
Daniels, 2016). In this dissertation, we will compare effectiveness of several alternative methods
applied to EHR collected at NYPH and CUMC clinical data warehouse (CDW).
1.5 Topic Modeling in EHR data
EHR data contains rich patient level features to build effective ITRs. Some information in EHRs
is documented in the form of text notes or similar structure that enable researchers to use topic
modeling techniques to better extract the information. Topic modeling techniques including latent
semantic analysis (LSA) (Landauer et al., 1998), probabilistic latent semantic analysis (pLSA)
(Hofmann, 1999) have been widely used to represent features in a lower dimensional space. LSA
is a well-known approach that maps count type data of documents to a reduced latent semantic
space based on Singular Value Decomposition (SVD) while pLSA improves LSA in a statistical way
that relies on a mixture decomposition (Hofmann, 1999). Furthermore, latent Dirichlet allocation
(LDA) is proposed as another generative probabilistic model, which overcomes some disadvantages
of pLSA such as generalizability to new documents and overfitting problems (Blei et al., 2003).
The rest of this dissertation is organized as follows. In Chapter 2, we introduce our pro-
posed matching-based learning method (M-learning) to estimate ITR. We show the advantages of
M-learning over two existing methods through simulation studies and apply it in a real world obser-
vational study. In Chapter 3, we propose a new framework in transferring information learned from
observational study in ITR estimation to randomized clinical trial. Moreover, we extend M-learning
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in Chapter 2 integrating with kernel method. In Chapter 4, we present a topic model based feature
extraction approach in two domains in EHR data and apply M-learning for ITR estimation using
the engineered features. We conclude this dissertation with limitations and future directions.
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Chapter 2
Matched Learning for Personalized
Treatment
2.1 Overview
Machine learning approaches provide valuable tools to estimate individualized treatment rules
(ITRs) and dynamic treatment rules (DTRs) due to their powerful computing capabilities. Previ-
ously proposed machine learning approaches include Q-learning (Watkins and Dayan, 1992; Qian
and Murphy, 2011), outcome weighted learning (O-learning) (Zhao et al., 2012), robust O-learning
(AOL) (Kang et al., 2014; Liu et al., 2018) and subgroup identification methods(Fu et al., 2016).
Most of these existing methods focus on analyzing randomized clinical trial (RCT) data. How-
ever, the ITRs estimated from RCTs may be inadequate to assist individualized treatment decision
making in real-world settings due to stringent inclusion/exclusion criteria of RCTs, a lack of gen-
eralizability, and a lack of evidence for long-term outcomes.
Large-scale electronic health records (EHRs) provide new opportunities to learn ITRs using
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real-world patient data. In recent years, access to clinical data warehouses and databases continues
to grow and an increasing trend of using EHRs for scientific research is observed (Weiskopf and
Weng, 2013; Hripcsak and Albers, 2013; Hripcsak et al., 2016). As exclusive evidence generated
from clinical trials is inadequate due to a lack of external validity, EHRs can serve as an important
complement to evidence-based research for personalized medicine. For instance, a broad range
of real-world medication use patterns not captured by RCTs were observed in EHRs (Hripcsak
et al., 2016). Furthermore, as compared to RCTs, using EHRs to learn ITRs has benefits such
as containing information on a large population over relatively longer time frames that reflects
patients’ care management and disease course in more realistic settings.
However, EHRs are not collected for research purposes and conducting research with EHRs
encounters great challenges. Critical issues including confounding bias and selection bias have been
discussed: completeness, accuracy, complexity, and bias (Hripcsak and Albers, 2013; Haneuse,
2016). In the context of estimating ITRs, common practice to adjust for confounding is inverse
probability weighting (IPW) of propensity scores with or without augmentation to achieve double
robustness (Zhang et al., 2012, 2013). The IPW approach needs a sophisticated model to estimate
propensity scores with high accuracy. Machine learning methods are thus proposed to predict
propensity scores (Lee et al., 2010, 2011; Austin and Stuart, 2015), but they may result in extreme
weights with high variability. In addition, the IPW approaches may not adequately balance covari-
ate distributions between treatment groups, especially when the distribution of propensity scores
has less overlap between treatment arms (Crump et al., 2009).
On the other hand, matching has been successfully used to estimate population average treat-
ment effects, including ratio matching (Smith, 1997), nearest neighbor matching (Dehejia and
Wahba, 1999), and full matching (Stuart, 2010; Hansen, 2004). However, to the best of our knowl-
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edge, there is no method to leverage advantages of matching to estimate personalized treatment
rules and apply to observational data such as EHRs.
In this chapter, we propose a machine learning approach, namely, Matched Learning (M-
learning), to estimate ITRs through matching treated and untreated subjects with an application
to EHRs. M-learning is a general framework that includes O-learning and AOL as special cases.
M-learning introduces matching-based value functions to match individual treatment responses un-
der alternative treatments and alleviate confounding. Various matching functions can be used to
compare outcomes for matched pairs to accommodate different types of data (continuous, discrete,
or ordinal) under a unified framework. The efficiency of M-learning can be improved by a denoise
procedure and double robust matching. The implementation is based on a matched-pairs weighted
support vector machine (SVM). We establish the Fisher consistency and convergence rate of M-
learning and conduct extensive simulation studies. We show that M-learning outperforms existing
methods when propensity scores are misspecified and in certain scenarios when unmeasured con-
founders are present. Lastly, we tackle challenges of EHRs, including confounding by indication,
confounding bias, and selection bias, and apply M-learning to estimate the optimal second-line
treatments for type 2 diabetes (T2D) patients to achieve better glycemic control or reduce major
complications.
2.2 Methodology
2.2.1 Individualized Treatment Rules (ITRs)
Let Hi denote the pre-treatment covariates and let Ai denote the binary treatment assignment
taking values from {−1, 1}. Let Ri denote the clinical outcome post treatment (reward), and
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assume a larger Ri is more desirable (e.g., symptom reduction). An ITR is a decision rule, D(Hi),
that maps the domain of Hi to the treatment choices in {−1, 1}. The value function associated
with D used to evaluate an ITR is defined as the expected post-treatment outcome by following D
to assign treatments, that is, V (D) = ED(Ri).
For RCTs, the assumption that the potential outcomes are independent of treatment assign-
ment given covariates is satisfied, and the treatment assignment probability, denoted by π(a, h) =
Pr(Ai = a|Hi = h), is known by design. O-learning proceeds by re-expressing the value function as














In an observational study, however, treatment propensities π(Ai, Hi) are unknown and need to be
estimated from data. Using the objective function (2.1) and IPW-based methods in observational
studies suffer from instability and increased variance especially when weights are highly variable. In
addition, IPW-based methods do not directly control the balance of covariate distributions between
treatment groups.
2.2.2 Matched Learning (M-learning)
When comparing different treatment responses, matching methods can be designed to ensure bal-
anced distribution at subgroup level and provide more flexible tools to control the matching quality
of important confounders in subgroups or even on individual subjects. For example, covariates
selection, distance metric and measure of covariates balance can be combined to optimize matching
(Sekhon and Grieve, 2012) and identify matching subjects to guarantee numerical stability, espe-
cially when some subgroup of patients rarely receive one particular treatment. Denote the matched
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set for subject i as Mi, which consists of subjects with opposite treatments but similar covariates
as subject i, where similarity is defined under a suitable distance metric. That is, we let
Mi = {j : Aj = −Ai, d(Hj , Hi) ≤ δi} ,
where d(·, ·) is a metric defined in the covariate space and δi is a pre-specified positive threshold to
determine the size of the matched set which may vary across subjects. For example, if we choose
Mi to be the nearest neighbor, then δi is the minimal distance between subject i and any other
subject with the opposite treatment. In some applications, subjects with empty matching sets may
be excluded. In this chapter, we use nearest neighbor in the matching step of M-learning in the
simulations and application, and study its theoretical properties.
M-learning is developed to maximize a matching-based value function defined in (3.1). The
motivation of M-learning is that when two subjects are matched in confounders or propensity
scores of treatments but are observed to receive opposite treatments, the subject with a larger
clinical outcome should be more likely to have received the optimal treatment among two options.
Based on this rationale, one expects that if j ∈ Mi and Rj ≥ Ri, then the optimal ITR for
subject i should more likely to be Aj , and vice versa. Furthermore, the likelihood is expected to
be greater if the difference between Rj and Ri is larger. Specifically, for any given ITR D, define
the matching-based value function as







I(Rj ≥ Ri,D(Hi) = −Ai)
+I(Rj ≤ Ri,D(Hi) = Ai)
}
g(|Rj −Ri|), (2.2)
where |Mi| is the size of Mi and g(·) is a monotonically increasing function specified by users to
weight different pairs of subjects. Typical choices of g(·) can be g(x) = 1 or g(x) = x. Furthermore,
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let D(H) = sign(f(H)) for some ITR decision function f , then the matching-based value function
(3.1) is equivalent to







I(f(Hi)Aisign(Rj −Ri) ≤ 0)g(|Rj −Ri|).







I(f(Hi)Aisign(Rj −Ri) ≥ 0)g(|Rj −Ri|), (2.3)
in order to identify the optimal ITR.
The objective function (2.3) can be further expanded by allowingMi = i (match subject i with
himself/herself). If in addition we replace Rj in (2.3) by zero (when Rj > 0 for all subjects) or the
smallest observed outcome when negative outcomes are present and choose g(x) = x, M-learning
reduces to the original O-learning in (Zhao et al., 2012). Similarly, if we replace Rj by subject
i’s predicted outcome estimated from a parametric model including only the main effects of Hi,
M-learning reduces to the single-stage AOL in (Liu et al., 2018). Thus, O-learning and single-stage
AOL are special cases of M-learning, where they compare the observed outcome Ri with a constant
or the predicted outcome given Hi averaged across treatments. In contrast, M-learning compares
observed individual outcomes from two subjects in the matched set, where the treatment assignment
is approximately “random” given Hi but the received treatments are opposite. Thus, M-learning
is more informative in taking account of information on patient’s outcome at the individual level
(Ri and Rj), instead of comparing a patient’s outcome with the predicted outcome averaged over
treatments (as done in O-learning or AOL).
Minimizing the matching-based value function (2.3) is not feasible due to the discontinuity of
the indicator function. Similar to O-learning, we replace the zero-one loss by other surrogate loss
functions. In particular, when using the hinge-loss, the objective function to be optimized is the
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loss function for the weighted support vector machine (SVM) with matched pairs:






φ(−f(Hi)Aisign(Rj −Ri))g(|Rj −Ri|) + λn‖f‖HK , (2.4)
where φ(x) = (1 − x)+, λn is a tuning parameter and HK is a reproducing kernel Hilbert space
(RKHS) with kernel function K(·, ·). The solution to M-learning is obtained by minimizing
Vn,φ(f ; g). In terms of implementation, the dual problem of (4.5) is a quadratic problem which can
be solved by any off-the-shelf quadratic programming packages.
Taking linear ITR decision rules as an example, we describe solution to the quadratic program-
ming problem using Lagrange multipliers. Assume f in Vn,φ(f ; g) is linear and f(h) = 〈β, h〉+ β0
where 〈·, ·〉 denotes the inner product operator and ‖f‖HK represents ‖f‖2 in Euclidean space. It










subject to: Aisign(Ri −Rj)(〈β,Hi〉+ β0) ≥ (1− ξij), ξij ≥ 0, ∀i and j ∈Mi,
where ξij is a slack variable that represents misclassification error for the jth subject in the matched
set of the ith subject, C is a cost parameter, and |Mi|−1g(|Rj−Ri|) is the individual-specific weight
in a weighted SVM framework.
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where we minimize with respect to β, β0 and ξij . By taking the respective derivatives and setting











αij = C|Mi|−1g(|Rj −Ri|)− µij ,∀i and j ∈Mi.

















αijαi′j′AiAi′sign(Ri −Rj)sign(Ri′ −Rj′)〈Hi, Hi′〉




j∈Mi αijAisign(Ri −Rj) = 0. In addition,
subject to Karush-Kuhn-Tucker conditions for ∀i and j ∈Mi (Zhao et al., 2012):
αij [Aisign(Ri −Rj)(HTi β + β0)− (1− ξij)] = 0,
µijξij = 0,
Aisign(Ri −Rj)(HTi β + β0)− (1− ξij) ≥ 0,
the solution to the primal and dual problem is optimal. It is straightforward to extend the algorithm
to other kernels (e.g., Gaussian kernel) and obtain a nonparametric ITR based on kernel function
K(·, ·) in the RKHS.
2.2.3 Improved M-Learning
To improve the performance of M-learning, we use a de-noise procedure first reported in (Liu et al.,
2018). We replace Ri by a surrogate residualized outcome R̃i = Ri − s(Hi) in Vn(D; g) for any
measurable function of Hi, denoted as s(Hi). These residualized outcomes remove the main effects
of covariates, which improves efficiency of identifying tailoring variables exhibiting quantitative or
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qualitative interaction with treatment. The residuals can be obtained through a regression model
and the value function to be maximized becomes







I(R̃j ≥ R̃i,D(Hi) = −Ai)
+I(R̃j ≤ R̃i,D(Hi) = Ai)
}
g(|R̃j − R̃i|).
As shown in (Liu et al., 2018), by removing the main effects of covariates, more stable weights are
used in the weighted SVM to boost efficiency in estimating ITRs.
Furthermore, prognostic scores can be incorporated into M-learning under the framework of
doubly robust matching estimator (DRME) proposed in (Antonelli et al., 2018). The DRME
uses both propensity scores and prognostic scores to construct a matching set M(i, θ), where
θ = (θ1, θ2)
T denotes parameters for the propensity score and prognostic score models:
π(H) = P (A = 1|H) = u1(HT θ1),m(H) = E(R|A = −1, H) = u2(HT θ2). (2.5)
(Antonelli et al., 2018) showed that only one of the two models in (2.5) is required to be correctly
specified to ensure consistency of DRME, which achieves double robustness. Applying DRME to
M-learning, both propensity scores and prognostic scores will be included in the matching step to
create informative matched pairs. The doubly robust M-learning is consistent even if one of the
propensity score model or prognostic model is misspecified, and it will be more efficient than regular
M-learning if both models are correctly specified. Note that M-learning can be applied to RCT
data where only prognostic scores need to be included in the matching step to improve efficiency.
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2.3 Theoretical Properties
In this section, we establish the theoretical properties including Fisher consistency, different choices
of g(x) and convergence rate of of M-learning.
2.3.1 Fisher Consistency
Theorem 2.3.1 Under regularity assumptions including maxni=1 δi → 0, and that the density of H
and E[R|H,A = 1] is continuously differentiable in the support of H, it holds that
Vn(f, g)→a.s V (f, g),
where





∣∣∣Ã = −A, H̃ = H]} ,
Ẽ is the expectation with respect to (R̃, H̃, Ã), an independent copy of (R,H,A). In addition, define










(R− r)|A = −1, H = h
]
,




∆g(r, h)dF (r|H = h),
where F (r|H = h) is the distribution of R = r given H = h and f∗ is the optimal function
minimizing V (f ; g).












(R̃−R)−|Ã = −1, H̃ = H]
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(R̃−R)−|Ã = 1, H̃ = H]
}]
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(R̃−R)|Ã = −1, H̃ = H]
∣∣∣H] .
In other words, if we define










(R− r)|A = −1, H = h
]
,




∆g(r, h)dF (r|H = h),
where F (r|H = h) is the distribution of R = r given H = h. 
Here we make a few remarks.
Remark 1. When g(x) = x and r = 0, i.e. ∆g(r, h) = E(R|A = 1, H = h)−E(R|A = −1, H = h),
Theorem 2.3.1 implies that the optimal treatment rule obtained from M-learning is the same as the
optimal rule from O-learning, and thus M-learning is Fisher consistent for the usual optimal ITR.
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Remark 2. When g(x) = 1, we obtain
∆g(r, h) = E [sign(R− r)|A = 1, H = h]− E [sign(R− r)|A = −1, H = h]
= P (R > r|A = 1, H = h)− P (R < r|A = 1, H = h)
−[P (R > r|A = −1, H = h)− P (R < r|A = −1, H = h)]
= 2[P (R > r|A = 1, H = h)− P (R > r|A = −1, H = h)].
Remark 2 suggests that for subjects with H = h, the optimal rule chooses the treatment with a
higher probability of having a greater outcome than the average outcome across treatments. Such
choice of g(x) ensures robustness against outliers of R. When R is an ordinal or binary random
variable, this choice is especially suitable. For example, consider an ordinal outcome with three
levels, then the optimal rule f∗(h) has a desirable property
sign(f∗(h)) = sign[AUC13(h)−AUC23(h)], (2.6)
where AUCjk(h) is the conditional AUC for comparing R = j with R = k for subjects with H = h.
More generally, the function ∆g(r, h) is similar to creating comparisons based on a reference level
r of the outcome. Therefore, for a particular target value r (e.g., the value under a universal “one-
size-fits-all” treatment assignment, or a clinically meaningful level for an ordinal outcome), one can
construct g(x) so that the weights concentrate on the difference from the reference value r.
Remark 3. Lastly, when applied to observational studies, the condition of no unmeasured con-
founders ensures that the optimal rule estimates the treatment with a higher potential outcome,
since ∆g(r, h) = E(R
(1)|H = h) − E(R(−1)|H = h), where R(k) denotes the potential outcome
under treatment k.
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2.3.2 Convergence Rate of M-Learning
In this section, we establish the convergence rate of the risk bound for the estimated decision rule.
We consider the nearest neighborhood matching, HK is the RKHS based on a Gaussian kernel
function with bandwidth σn, and assume R and H are bounded. Furthermore, we need the follow-
ing assumptions:
(A.1) The density of H = h with respect to the dominating measure and E(R|A = a,H = h) are
continuously differentiable in H’s support for a = −1 and 1. Moreover, the density of H is bounded
from below on the support of H, denoted by XH .
(A.2) The probability measure has a geometric noise exponent α > 0 as in Definition 2.3 of (Stein-
wart and Scovel, 2007). That is, if let τH be the distance from any H to the decision boundary
{h : f∗(h) = 0}, it holds
E[|f∗(H)| exp{−τ2H/t}] ≤ ctαd/2, t > 0.
(A.3) There exists γ > 0 and r0 > 0 such that |XH ∩ B(h, r)| ≥ γ|B(h, r)| for any h ∈ XH and
0 < r < r0, where B(h, r) is a ball centered at h with radius r, and |A| denotes the volume of set
A in XH .
Condition (A.1) is necessary to ensure the conistency of approximation in the nearest-neighbor
based matching. Condition (A.2) is commonly assumed for SVMs and a similar condition has
been considered for classification problem (c.f., (Steinwart and Scovel, 2007)) and establishing the
learning rate for ITRs (Zhao et al., 2012). When the decision rule is completely separable, the
exponent α can be as large as possible. The third condition (A.3) is used to obtain the convergence
for the nearest-neighbor estimator (Devroye et al., 2013)
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Theorem 2.3.2 Under the above assumptions and letting σn = λ
1/p(1+α)
n , it holds



















where β1 = p/4 + (1/2− p/8)d/[(1 +α)], β2 = 1/2p(1 +α) + 1/2, and mn is the size of the nearest
neighbor.
Note that the convergence rate will depend on the dimension, the geometric noise exponent
α and the choice of tuning parameter σn. Moreover, we observe that when λn = n
−θ with a
constant θ and the size of nearest-neighbor equals to n2/(p+2), the polynomial convergence rate can
be attained.
Proof of Theorem 2.3.2. For convenience of notation, we use ‖ · ‖n to denote the norm in the
RKHS and omit g in the definition of the loss function, i.e., denote Ln(f ; g) as Ln(f). We use c
to denote a constant that is independent of n in the following proof. The M-learning algorithm







Here, P̃n and P̃ to be used later refer to the measures with respect to an independent copy of






Q(R,A,H; f) = Ẽ
[
φ(−f(H)Asign(R̃−R))g(|R̃−R|)
∣∣∣H̃ = H] .
Clearly, Ln(f) = PnQn(R,A,H; f) + λn‖f‖2n.
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Let Lφ(f) = E[Q(R,A,H; f)]. From the general property of the weighted hinge-loss as shown
in Theorem 3.2 of (Zhao et al., 2012), we have





Therefore, it is sufficient to obtain a bound for the right-hand side. First, since Lφn(f̂) ≤ Lφn(0),
























−Pn [Q(R,A,H; f0n)−Qn(R,A,H; f0n)]
+Ln(f̂)− λn‖f̂‖2n − Ln(f0n)
+E [Q(R,A,H; f0n)] + λn‖f0n‖2n − V (f∗)
≤ sup
f :‖f‖n≤λ−1/2n
∣∣∣(Pn −P)Q(R,A,H; f)∣∣∣ (I)
+ sup
R,A,H
∣∣∣Q(R,A,H; f̂)−Qn(R,A,H; f̂)∣∣∣ (II)
+ sup
R,A,H
∣∣∣Q(R,A,H; f0n)−Qn(R,A,H; f0n)∣∣∣ (III)
+E [Q(R,A,H; f0n)] + λn‖f0n‖2n − V (f∗). (IV)
We refer the terms in the right-hand side as (I), (II), (III) and (IV) in turn.
For term (I), we compute the bracket covering number of some finite balls in HK . First, from
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Theorem 3.1 in (Steinwart and Scovel, 2007), the entropy number for the unit ball in HK , denoted
by On, satisfies
logN (ε,On, ‖ · ‖∞) ≤ cσ−(1−p/4)dn ε−p
for a constant c depending on p and d, so it yields




f : f ∈ Hσn , ‖f‖n ≤ λ−1/2n )
}
, ‖ · ‖L2(P )) ≤ cσ−(1−p/4)dn ε−p(1/λn)p/2.
Note that Q(R,A,H; f) is Lipschitz continuous with respect to f in the sense that
∣∣∣Q(R,A,H; f1)−Q(R,A,H; f2)∣∣∣ ≤ c|f1(H)− f2(H)|,
where c is a constant bounding g(|R− R̃|). Therefore, we obtain
logN[](ε,
{
Q(R,A,H; f) : ‖f‖n ≤ λ−1/2n
}
, ‖ · ‖L2(P )) ≤ cσ−(1−p/4)dn ε−p/λp/2n .










Q(R,A,H; f) : ‖f‖n ≤ λ−1/2n
}






For term (II), since ‖f̂‖n ≤ λ−1/2n , Theorem 4.48 in (Steinwart and Christmann, 2008), implies




n . Using the uniform
convergence rate result for nearest-neighbor estimators (Devroye et al., 2013; Jiang, 2017) and
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The same bound holds for term (III). Finally, the last term is the approximation error as de-
fined in (Steinwart and Christmann, 2008) but with a different definition of the loss function as
Q(R,A,H; f). We can follow exactly the same argument in Theorem 2.7 of (Steinwart and Christ-
mann, 2008) to obtain its upper bound as c(σ−pn λn + σ
αp
n ) for any positive α.

























By choosing σn = λ
1/p(1+α)
n , we obtain the result in Theorem 2.3.2.
As a remark, the tail probability, P (|V (f∗; g)− V (f̂ ; g)| ≥ t) where t > 0, can also be obtained
under similar arguments. Theorem 2.3.2 provides a stochastic bound for term (I). One can obtain
the bound of the tail probability for this term using the tail bound for empirical processes (Chapter
2.14, (Van Der Vaart and Wellner, 1996)). Then the tail probability, P (|V (f∗; g) − V (f̂ ; g)| ≥ t),
will follow. 
2.4 Simulation Studies
We conducted extensive simulation studies to compare M-learning with Q-learning and single-stage
AOL as improved O-learning (Liu et al., 2018). Data were simulated under an observational study
design where treatment assignment depends on pre-treatment variables H. Simulation settings and
analyses we considered include: (1) No unmeasured confounder and the propensity score model
given H is correctly specified in the analyses; (2) No unmeasured confounder but the propensity
score model is misspecified; and (3) Unmeasured confounders are present and some components of
H are not observed and not included in the analyses.
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In these simulations, one-to-one matching with replacement was used and features were matched
using shortest Euclidean distance function (one nearest-neighbor). The tuning parameters for AOL
and M-learning (including choice of kernel as linear or Gaussian, inverse radius, and cost C) were
selected by three-fold cross validation. The value function corresponding to the estimated optimal
rule was computed on a large independent testing set with a sample size of 10, 000 using empirical
average. Q-learning was fit with a linear model including feature variables and their interaction
with treatment as covariates. We varied sample size of training data from 100 to 1, 000 and repeated
the simulations 100 times.
We first considered continuous responses in two settings:
S1 : R = 2H3 −H4 +A(H1 −H2) + 6sign(H1) +N(0, 1)
and
S2 : R = 1 + 2H1 +H2 + 0.5H3 +A(H2 +H
2
1 − 1) + 6sign(H1) +N(0, 1).
Uncorrelated feature variables Hk with standard normal distributions were simulated. Since het-
erogeneity and clustering effects are observed in the real-world patient population (e.g., Figure 2.5
of NYPH EHRs in Appendix A), we considered the distribution of reward outcomes to be clustered
in strata depending on the first feature variable H1. The true optimal treatment decision boundary
is linear in setting S1, and nonlinear in setting S2. The true optimal value is 1.20 in S1 and 2.29
in S2. In the continuous response scenario, g(x) = x was used for M-learning. In setting S1 and
S2, M-learning and doubly robust M-learning by stratifying on prognostic scores (referred to as
“M-learning Stratified” in Figure 2.1 and 2.2) were considered. For the latter, prognostic scores
were obtained using random forest. Prognostic factors used in the matching step were created by
dichotomizing the prognostic scores based on the median split.
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In the first set of simulations, distribution of A depends on H and no unmeasured confounder
is present. Clinical response outcomes were simulated under setting S1 and S2, and the true
propensity model was specified as P (A = 1|H) = expit(1 + 2H1 +H2). In this case, H1 and H2 are
observed confounders. The propensity scores were estimated through a logistic regression model
with treatment as binary outcome and features H1, H2 as linear predictors. On average, 64% of
subjects received an active treatment and 36% received a control treatment. Simulation results are
presented in the top panel of Figure 2.1. For setting S1, Q-learning has the best performance since
the linear function is the true optimal treatment separation boundary. Doubly robust M-learning
performs similarly as Q-learning with larger sample size. It is clear that doubly robust M-learning
improves efficiency. For S2 with a nonlinear boundary, both M-learning and doubly robust M-
learning achieve a higher empirical value than AOL and Q-learning. In this case Q-learning and
AOL lose efficiency because they do not capture the information in prognostic scores, even though
the propensity scores were consistently estimated.
In the second set of simulations, the true propensity score model was specified as P (A = 1|H) =
expit(1 + exp(H2)). The propensity scores were estimated through a logistic regression model with
linear predictors, and thus the model was misspecified. On average, 88% of subjects received
one treatment and 12% received the other. Simulation results are presented in the bottom panel
of Figure 2.1. In both setting S1 and S2, the results suggest that M-learning is more robust to
misspecified propensity model compared to Q-learning and O-learning. The best performance is
achieved by the doubly robust M-learning, where the estimated value function is very close to the
true optimal value with a large sample size. Matching using prognostic scores in doubly robust
M-learning has protected against deteriorated performance when the propensity score model is
misspecified.
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(d) Setting S2, propensity score model misspecified
Figure 2.1: Value comparison of four methods with propensity scores correctly specified (top panel) and
misspecified (bottom panel). The numbers at the top of each subfigure are mean values.
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In the third set of simulations, we considered presence of unmeasured confounders. The clinical
outcomes were simulated as
S3 : R = 2H3 −H4 +A(H1 −H2 +X) + 6sign(H1) +N(0, 1)
and
S4 : R = 1 + 2H1 +H2 + 0.5H3 +A(H2 +H
2
1 +X − 1) + 6sign(H1) +N(0, 1)
where P (A = 1|H,X) = expit(1 + R(−1) − R(1) + 2X + H1) and X is an unmeasured confounder
(not included in any analysis in any method) and R(−1), R(1) are potential outcomes under each
treatment.
After introducing unmeasured confounding, the true optimal value function is 1.37 in S3 and
2.61 in S4. From Figure 2.2, we see that in S3 with a linear decision boundary, Q-learning performs
the best. Doubly robust M-learning has a higher mean value than M-learning. Matching-based
methods have an advantage over AOL. Specifically, the value function of ITR estimated by AOL
has a large variability, especially when the sample size is small. In S4 with nonlinear decision
boundary, two M-learnings much outperform AOL and Q-learning. In this case, the unmeasured
confounder has a greater impact on AOL and Q-learning than M-learning.
We also examine M-learning with ordinal outcomes and report results in Appendix A.1. For
linear decision boundary, since ordinal outcomes were generated by discretizing a continuous out-
come, M-learning does not give an advantage over Q-learning and AOL. For nonlinear boundary,
M-learning using matching function g(x) = 1 and g(x) = x both achieves a higher value than
Q-learning and AOL.
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(b) Setting S4: unmeasured confounders present
Figure 2.2: Value comparison of four methods in the presence of unmeasured confounders. The numbers
at the top of each subfigure are mean values.
2.5 Applications
We apply various methods to a large clinical data warehouse (CDW) at New York Presbyterian
Hospital (NYPH). NYPH CDW is one of the earliest pioneer CDWs in the United States developed
25 years ago, long before the wide adoption of EHRs and informatics methods. The database
encompasses about 4.5 million patients in the New York City population, making it a useful data
source for research and supports new research initiatives including eMERGE (Gottesman et al.,
2013) and precision medicine initiative. The details of the informatics technology of NYPH CDW
is described in Figure 2.3.
Our research goal is to optimize treatment sequence for T2D patients based on their person-
specific characteristics. Current treatment guideline recommends metformin (MET) as the first
line treatment for T2D patients (Diabetes Control and Complications Trial Research Group, 1993).
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Figure 2.3: Flowchart of EHR data processing procedures
Literature reveals barriers of timely insulin initiation in clinical practice when patients do not
achieve adequate glycemic control by using metformin alone, and the optimal sequence of treatments
for insulin therapy versus second-line oral hypoglycemic agents (OHA) largely remains unknown
(American Diabetes Association, 2014). In this work, we aim to estimate the optimal second-line
treatment for T2D patients who received MET as the first-line treatment using real-world EHRs.
Targeting the second-line treatments (metformin + insulin versus metformin + SFU, where SFU
refers to oral agent sulfonylureas that includes glyburide and glipizide) partially reduces confounding
by indication, where treatment uncertainty is present in real-world practice.
We excluded subjects with extreme baseline HbA1c values (greater than 10%), and used a new-
user cohort design (Ray, 2003). Such design is often used in other studies of EHRs to properly
capture time-varying confounding and early treatment responses. Specifically, the study design is
illustrated in Figure 2.4. Subjects who started a second-line treatment (new users) are anchored at
the treatment initiation (index date), and information before and after index date will be analyzed.
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Figure 2.4: T2D EHR Study Design
Subjects were included in the analyses if they had MET as the first-line treatment, had insulin or
SFU as the second-line treatment, and had at least one observation post index date. The median
baseline period was around one year and the median follow up time post second-line treatment was
about 18 months.
In the following sections 2.5.1 and 2.5.2, we describe details of patient records extraction and
feature extraction.
2.5.1 T2D Patient EHRs
Quality of the information collected in the EHRs is essential for learning treatment strategies
from EHRs. The current design of NYPH CDW uses the cutting-edge informatics technologies
and utilizes a quality control process that helps accuracy of feature extraction/curation (e.g., all
data have been normalized using the medical entities dictionary to facilitate semantic informa-
tion retrieval). Several studies were launched to investigate data quality including completeness,
correctness, concordance, plausibility, and currency (Weiskopf and Weng, 2013; Fort et al., 2014),
where recent EHRs in NYPH CDW were deemed to possess better completeness and accuracy
(Weiskopf and Weng, 2013; Hripcsak et al., 2016). The main domains of the information in EHRs
include demographics, in-patient and out-patient medication prescriptions, ICD-9 diagnosis codes,
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and laboratory tests, which were longitudinally documented in the CDW. In order to be more com-
patible with other observational databases as part of the Observational Health Data Sciences and
Informatics (OHDSI, https://ohdsi.org/), clinical data warehouse at NYPH has been recently
converted to the OMOP Common Data Model version 5.0 to support real-world evidence genera-
tion using scalable observational data. The quality of these EHR data was found to be suitable for
studying treatment pathways of common diseases including T2D (Hripcsak et al., 2016).
Patients aged 18 or older who had at least one T2D diagnosis between 1/1/2008 to 12/31/2012
and were prescribed with metformin were included in the analysis. There were 1,279 patients
who had a second-line treatment in the CDW EHRs during the 5 year window. Medication pre-
scriptions, laboratory tests, demographics, and ICD-9 diagnosis codes from over 50, 000 patients
were extracted. The details of data pre-processing procedures and intermediate datasets are in the
flowchart in Figure 2.3. Figure 2.5 displays a heatmap of representative patients with 17 feature
variables extracted from the CDW EHRs, among which ICD diagnosis and co-medication counts
were derived from over 8, 000 unique variables. To explore patient heterogeneity, features were
standardized and a hierarchical clustering analysis with Euclidean distance clustered patients into
3 groups: (1) a moderately ill group with a slow rate of change in glycemic measures (HbA1c,
glucose) and a regular, frequent documentation pattern; (2) a moderately ill group with slow pro-
gression but a less frequent measurement pattern, less co-morbidity and non-diabetic medications;
and (3) a fast progression group with less measurements. The cluster membership was included as
a feature variable to construct the ITR.













































































































Figure 2.5: Heatmap of 17 extracted feature variables from EHRs of representative T2D patients in NYPH
CDW.
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2.5.2 Handling Challenges of the Analyses of EHRs
Three major challenges need to be addressed when conducting clinical research using EHR data
(Haneuse, 2016). In our context, these issues are: confounding bias due to factors associated
with treatment selection (i.e., insulin versus SFU) and outcome; selection bias due to missing post
second-line treatment outcome (some patients had no follow up HbA1c test records and thus were
not included in the analyses), and presence of missing feature variables. EHRs provide information
that not only reflects patient’s health status but also the healthcare process, shedding lights on
how data are recorded (Hripcsak and Albers, 2013).
To extract such information, descriptive analysis in Figure 2.6 indicates that distinct measure-
ment patterns of glucose tests are present for different treatments. For example, the measurement
process of glucose tests shows a high discriminant power (y-axis, histogram on the side) between
patients who received insulin as a second-line treatment (MET+insulin) and those who received
glyburide or glipizide (MET+SFU); this information is thus useful for creating propensity scores
and matching. The temporal process of measurement time intensity patterns is also highly discrim-
inant (x-axis, histogram on the top) and useful for computing treatment propensities. Figure A.1
shows a similar discriminant power for HbA1c tests.
We constructed feature variables of lab measurement patterns by discretizing a two-dimensional
feature space of lab test values versus gap time between two consecutive measurements in Figure 2.6,
A.1. Indicators of subgroup membership based on low, medium, and high quartiles were created.
For example, the first subgroup indicates subject with a “low glucose value and short measurement
gap”. In addition, we constructed features informative of treatment response such as initial lab test
values and rate of change of lab values before treatment initiation from longitudinal records of four
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(d) Metformin + Glipizide
Figure 2.6: Glucose values and measurement intensity (Time 0: time at first line treatment (MET)
prescription)
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major tests: HbA1c, glucose, high density lipoprotein (HDL) and low density lipoprotein (LDL).
The initial test values and rates of change were estimated from a linear mixed effects model. These
features are also potential prognostic factors associated with post index date HbA1c levels, and are
used to create prognostic scores.
We constructed patterns of laboratory measurements to handle challenges in the analyses of
EHRs (e.g., confounding bias and selection bias). Extracted features encompass information from
five domains (Figure 2.3): demographics, medication prescription, ICD diagnosis codes, laboratory
test values, and lab test measurement patterns. Propensity scores were estimated using two distinct
logistic regression models for lab measurement pattern features and demographics covariates. The
matching step in M-learning was performed using extracted features from lab test values and
rates of change (HbA1c, glucose, HDL, LDL, BMI), ICD counts, and two propensity scores. In
addition, to improve efficiency and perform doubly robust matching, we also included a prognostic
score estimated from a linear regression model in the matching step. Mahalanobis distance was the
matching similarity measure and one nearest-neighbor was used to select matched pairs. To address
selection bias in missing post-treatment outcomes, we used the IPW method and constructed a
logistic regression model predicting whether a subject had any post treatment lab measure to
compute the weights. To handle incompleteness in features, imputation with chained equations
was used (Buuren and Groothuis-Oudshoorn, 2011).
2.5.3 Analysis Results
Our final EHR data for learning optimal ITR consists of 740 patients, among whom 292 (39%)
received insulin as the second-line treatment while 448 (61%) received SFU. The outcome is the
HbA1c level (%) at 6 month post second-line treatment initiation estimated from a linear mixed
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effect model with subject-specific random intercepts and random slopes. Feature variables for
learning optimal ITR include initial lab test values (HbA1c, glucose, HDL, LDL, BMI) and rate
of change of measurements before index date, demographic variables, the cluster membership esti-
mated from a subset of features (Figure 2.5), counts of other non-glycemic medications and counts
of positive ICD diagnosis codes. Two-fold cross validation was used to estimate the value function
of fitted ITRs.
We divided our cohort to two groups according to the initial HbA1c level (high baseline HbA1c
group: >= 8.5 and low baseline HbA1c group: < 8.5) and analyzed the groups separately to
further reduce patient heterogeneity. We compared the cross-validated value function of doubly
robust M-learning to non-personalized universal rules, Q-learning, and AOL. In the rest of this
section, we refer doubly robust M-learning as M-learning and AOL as O-learning for simplicity.
The results are displayed in Figure 2.7 and Table 2.1. In the low baseline group, there were 380
patients in total (240 received SFU, 140 received insulin). For universal rules, the IPW-adjusted
mean HbA1c level is 7.99 for those treated by SFU and is 8.05 for insulin. M-learning achieves
the best glycemic control among all methods (lowest post-treatment HbA1c at 6 month) with a
median and mean of 7.85 that is much lower than both universal rules. Q-learning does not provide
much improvement compared to universal rules and its estimated post-treatment HbA1c is slightly
smaller than assigning SFU to all. In the high baseline group, there were 152 patients who received
insulin and 208 received SFU. The universal rules for HbA1c level in SFU group is 8.90 and in
insulin group is 9.21. O-learning and M-learning have very similar performance and both reduce
the average post-treatment HbA1c level to 8.57, again much lower than universal rules.
By examining M-learning in all patients using a linear kernel in the low baseline group, we
identified several features that are most informative in determining the optimal treatment: pre-
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treatment rate of change of BMI, initial value of glucose and LDL at the index date, co-medication
count, patient cluster membership and race. These feature variables can be considered by healthcare
practitioner when recommending second-line treatment for T2D patients. There were 263 (69%) of
the 380 patients predicted to have “MET + SFU” as the optimal choice and 117 (31%) with “MET
+ Insulin” as the optimal choice. Of the 240 patients who were prescribed SFU as the second-
line treatment, majority of times (66%) medication was also the predicted optimal treatment in
terms of lowering HbA1c level. In contrast, among the 140 patients who were prescribed insulin,
only 36 (26%) were optimal. In the high baseline group, the important features we identified are
initial value of HDL, age, sex and patient cluster membership. 294 (82%) of the 360 patients were
recommended to “MET + SFU”. Of the 208 patients who were prescribed SFU, 168 (81%) also
had as the predicted optimal treatment. Among the 152 patients who received insulin treatment,
only 26 (17%) were optimal. These results seem to suggest that some patients who received insulin
as the second-line treatment might be better treated with SFU.
However, (Bianchi and Del Prato, 2011) suggested that tight glycemic control need to be studied
carefully in different group of T2D patients to determine the balance of its negative and positive
effect and treatment personalization should be recommended considering multiple factors such as
risk of complications (e.g. cardiovascular events). Given a low rate of insulin predicted to be opti-
mal among patients who were treated with insulin, we explored whether insulin could be prescribed
based on other considerations such as risk of complications in addition to achieving glycemic con-
trol. We estimated the optimal ITR that reduces major complications of T2D measured by three
ICD diagnosis counts including essential hypertension, hyperlipidemia and hypercholesterolemia as
ordinal outcomes (0, 1, 2, 3). M-learning was implemented with g(x) = x. The results are dis-
played in Figure 2.8 and Table 2.2. In the low baseline group, O-learning is moderately better than
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M-learning with an average count of 0.72. Based on M-learning, SFU was predicted to be optimal
for 274 (72%) patients. Among patients who indeed received SFU, 175 (73%) were predicted to
be optimal with regarding to reducing complications while 41 (29%) of the patients who received
insulin were predicted to be optimal. In the high baseline group, M-learning performs the best with
an average value of 0.84. Further investigation shows that insulin was predicted to be the optimal
choice for 234 (65%) patients. In this group, among 152 patients who indeed received insulin, 106
(70%) were predicted to be optimal with regard to reducing complications, while only 80 (38%) of
the patients who received SFU were predicted to be optimal.
In conclusion, the optimal ITRs outperform universal rules in all groups for both outcomes.
M-learning performs better than Q-learning in all cases and better than O-learning in most cases.
In addition, the proportion of patients treated by insulin and with insulin predicted to be optimal
is higher when considering reducing complications as the outcome as compared to controlling for
HbA1c (from 17% to 70% in the high baseline group). This result suggests that the rationale to
prescribe insulin might be also based on concerns of complications especially when the baseline
HbA1c is high (greater than 8.5%).
2.6 Discussion
We have proposed a machine learning approach based on matching, M-learning, to estimate the
optimal ITR from observational data. We show that M-learning is a general approach that includes
O-learning and some of its derivatives as special case and it satisfies Fisher consistency. A general
matching function is proposed to analyze continuous or discrete outcomes where in some cases
the objective function maximizes a certain function of AUC. The choice of g(·) function provides
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Figure 2.7: Empirical value function of HbA1c in EHR data with 100 2-fold cross-validations (a
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Figure 2.8: Empirical value function of ICD diagnosis count in EHR data with 100 2-fold cross-
validations (a low value is desirable)
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Table 2.1: Cross-validated Empirical Value Function for
HbA1c
High Baseline Group
Universal rules: MET + SFU: 8.90, MET + Insulin: 9.21
ITR Method Mean (Std) Median (Q1, Q3)
Q-Learning 8.72 (0.124) 8.70 (8.64, 8.75)
O-learning 8.57 (0.038) 8.57 (8.54, 8.60)
M-Learning 8.57 (0.045) 8.57 (8.55, 8.59)
Low Baseline Group
Universal rules: MET + SFU: 7.99, MET + Insulin: 8.05
ITR Method Mean (Std) Median (Q1, Q3)
Q-Learning 7.94 (0.083) 7.94 (7.88, 7.99)
O-learning 7.87 (0.061) 7.88 (7.83, 7.91)
M-Learning 7.85 (0.068) 7.85 (7.82, 7.90)
Table 2.2: Cross-validated Empirical Value Function for the
Number of Major Complications
High Baseline Group
Universal rules: MET + SFU: 0.94, MET + Insulin: 0.89
ITR Method Mean (Std) Median (Q1, Q3)
Q-Learning 0.88 (0.078) 0.88 (0.83, 0.93)
O-Learning 0.86 (0.050) 0.87 (0.83, 0.90)
M-Learning 0.84 (0.068) 0.83 (0.80, 0.88)
Low Baseline Group
Universal rules: MET + SFU: 0.89, MET + Insulin: 1.00
ITR Method Mean (Std) Median (Q1, Q3)
Q-Learning 0.81 (0.063) 0.81 (0.76, 0.85)
O-Learning 0.72 (0.033) 0.72 (0.70, 0.74)
M-Learning 0.73 (0.032) 0.73 (0.71, 0.75)
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a flexible tool to weight outcome measures: g(x) = 1 gives the most robust estimation which
only concerns with the ranking of outcomes; while other robust choices can prevent sensitivity to
outliers of Ri’s. Moreover, multivariate outcomes can be incorporated in the M-learning framework
by creating suitable g function. The matching function g(x) can be selected from a pool of non-
decreasing functions to estimate the optimal ITRs in a data-driven way, which may lead to a better
post treatment response.
M-learning has a few advantages over O-learning or other IPW-based methods. It does not rely
on the validity of propensity score models and no inverse weighting is involved. Thus instability
can be avoided when there are extremely small weights. The choice ofMi in M-learning is flexible
and can include a large suite of matching tools including nearest neighbor, metrics defined on
a dimension-reduced space determined by propensity scores or prognostic scores, yielding double
robustness. For example, methods based on greedy matching or optimal matching algorithm are
available to be implemented in M-learning. Different calipers can also be specified for individual
subject and hence allow more “personalization”. This strategy will introduce more flexibility but
at the price of some computational complexity.
The choice of matching variables is important in M-learning. The performance of M-learning
may be affected by the presence of high-dimensional features in the matching step. We suggest a
dimension reduction approach to match on a lower dimensional space consisting of propensity score,
prognostic score, and/or cluster membership of patients. We also included some key covariates
as part of the matching criteria. A more general practical guide during the matching step is:
first, choose major confounders according to domain knowledge or preliminary studies to achieve
covariates balance; second, construct several propensity scores to reduce the dimensionality of the
space of matching covariates; and third, include prognostic scores in order to improve robustness
CHAPTER 2. MATCHED LEARNING FOR PERSONALIZED TREATMENT 45
and efficiency. In the EHR analysis here, we considered this general guideline and constructed
domain-wise propensity scores as well as prognostic scores, and matching was performed based
on these scores. Other variable selection techniques can be considered, for example, to estimate
propensity and prognostic scores by penalized regression.
Single-stage M-learning can be generalized to multi-stage setting by changing the value function
V (D) to a corresponding matching-based value function involving multiple stages and applying the
backward learning methods (Liu et al., 2018). In each stage, M-learning will have the flexibility
to choose different matching function and matched features. Furthermore, an extension to handle
efficacy and safety outcomes (e.g., glycemic control and risk of complications) simultaneously when
learning ITR is desirable. Here we only considered choosing between two treatment options. M-
learning is ready to be generalized to more than two treatments by, for example, adopting one-
versus-one or one-versus-all strategies for multicategory learning (Allwein et al., 2001). Lastly,
our analyses were restricted to EHRs from those who had at least one second-line T2D treatment
documented at a single academic medical center. It would be of interest to examine the performance
of our methods on other EHR databases.
CHAPTER 3. DOMAIN ADAPTION TRANSFER LEARNING 46
Chapter 3
Domain Adaption Transfer Learning
3.1 Overview
Personalized medicine based on individualized treatment rules or recommendations (ITRs) has been
proposed as an alternative to population based strategy (Hamburg and Collins, 2010; Collins and
Varmus, 2015). Personalized treatment decision making becomes closer to reality than before, due
to recent advances in modern technologies that produce a large amount of patient-specific data. In
particular, patients’ electronic health records (EHRs), which contain medical history, laboratory
measures, and disease diagnosis for a large number of patients over years, provide rich information
about each patient’s comorbiditiy, treatment history and outcomes in a real-world setting. How to
incorporate such real-world evidence to learn ITRs remains an important and challenging research
question in the modern era of personalized medicine.
Recent development of statistical and machine learning methods for optimizing ITRs aims to
assist healthcare providers to prescribe the right therapy to the right patient at the point of care
(Chakraborty and Moodie, 2013; Collins and Varmus, 2015). Patients can have improved clin-
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ical benefits and adherence to the treatment with the prescribed optimal individualized therapy
(Chakraborty and Moodie, 2013). For healthcare providers and industry, it is of interests to revolu-
tionize personalized treatment by estimating individualized treatment rules (ITRs). These methods
include regression-based approaches that estimate the conditional mean of treatment outcomes or
their contrasts given treatments and patient’s feature variables, to name a few, Q-learning (Qian
and Murphy, 2011; Chakraborty and Moodie, 2013), A-learning (Murphy, 2003) and G-computation
(Lavori and Dawson, 2004; Moodie et al., 2007). Alternatively, one can directly optimize a value
function or its equivalence to learn optimal ITRs. These methods include outcome-weighted learn-
ing (O-learning, (Zhao et al., 2012)), a doubly-robust version of O-learning (Liu et al., 2018) and
more recently, matching-based M-learning (Wu et al., 2019).
Many existing methods are developed in the context of randomized controlled trials (RCTs), for
which the estimated ITRs are known to be consistent. However, although RCTs have high internal
validity, they are usually conducted under specific inclusion/exclusion criteria, which potentially
limits the generalizability of the resulting ITRs to a broader real-world patient population. In fact,
some findings of treatment efficacy in clinical trials may not be directly translated to a general
patient population in the real world clinical setting with the same condition (Haynes, 1999). On
the other hand, real-world data such as EHRs document medical practices in a real-world setting.
Therefore, in order to improve the generalizability of the ITRs, it is desirable to incorporate the
EHR evidence when learning the ITRs in clinical trials. However, due to the presence of unmeasured
confounding in the EHR data and the potential differences between the trial and EHR patients,
how to effectively incorporate the EHR data poses a challenging issue.
In this chapter, we propose a novel method to improve learning ITRs from RCTs borrowing
evidence from EHRs. First, we pre-train two “super” feature mappings from the EHR data: one is
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a probability feature that estimates the propensity of physician’s choice of a given treatment being
the same as the optimal treatment for an EHR patient; the other is a benefit feature that reflects
the observed benefit in the real world under the optimal treatment. Since the prescribed treatments
in the EHR data are likely to be at least beneficial (e.g., better than random assignment) (Wallace
et al., 2016), the “super” features learned in the EHRs can be potentially informative of the optimal
ITRs for real world patients as well as RCT patients. Next, we augment the feature space of the
clinical trial data by these two features when learning final ITRs using only trial patients. To
enhance the signal from super features, we propose stratified learning to estimate the optimal ITRs
separately within each stratum defined by the super features. Particularly, we apply Q-learning
and a modified M-learning to estimate the optimal ITRs in each stratum.
We provide theoretical justification of several advantages of the proposed method. First, since
the final optimal ITRs are estimated using the RCT data, they remain valid due to the virtue
of randomization regardless of whether EHR super features are used. Second, since the super
features are informative of the treatment benefit and optimal ITRs, our learning method, which
is based on stratifying by super features, should yield more precise estimation of ITRs compared
to the methods without these features. Finally, the included super features are learned using the
EHR data so they are very likely to be correlated with the actual optimal treatments for the EHR
population. Thus, even if the trial population may be different from the EHR population, the
optimal ITRs from our method, which are partially directed by the super features, are potentially
more generalizable to the EHR population. As a note, the proposed method falls into a general
framework of transfer learning in machine learning community, which refers to domain adaptation
by allowing different assumptions in different domains with a single task in hand (Pan and Yang,
2010). Reweighting or data transformation methods are commonly used techniques to handle
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challenges in domain adaptation (Zhang et al., 2013). However, our method does not rely on
any weighting or transformation, but instead, extracts most informative features to improve ITR
estimation in RCTs.
We conduct simulation studies to demonstrate performance of the domain adaptation learn-
ing compared to the methods without using information from the EHRs. Lastly, we apply our
method to derive super features from EHRs of type 2 diabetes (T2D) patients to improve learning
individualized insulin therapies from a T2D randomized trial, DURABLE study (Fahrbach et al.,
2008). We show that directly applying ITRs learned from one domain to the other performs even
worse than universal treatment strategy, while proposed domain adaptation leads to improvement
in value function. We conclude the chapter with discussions and future extensions.
3.2 Method to Improve ITRs by Borrowing Evidence from EHRs
3.2.1 Learning the optimal ITR using RCT data
Let X denote the features collected prior to treatment and let A denote the binary treatment
assignment coded as {−1, 1}. Let Ri denote the clinical outcome after treatment. Assume a larger
R corresponds to better treatment outcome (e.g., reduction in symptoms). An ITR is a decision
rule, denoted as D(X), which maps the feature space to the treatment decision space. The value
function associated with D used to evaluate an ITR is defined as the expected post-treatment
outcome by following D to assign treatments, that is, V (D) = ED(R), where ED refers to the
expectation under a probability distribution with A = D(X). When the treatment assignment
mechanism is known (e.g., for a RCT), this expectation can be equivalently expressed as
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where π(a, x) is the randomization probability for A = a given X = x. Thus, the goal of learning
the optimal ITR is to find D(·) that maximizes V (D). The corresponding empirical value function









There are many statistical and machine learning methods developed to estimate the optimal
ITR. They can all be unified into maximizing some surrogates of Vn(D), in which different weights
and loss functions are used to replace R and I(A = D(X)), respectively. For example, in terms of
the surrogate weight for R, Q-learning replaces R by the estimated treatment benefit based on a
regression model (Qian and Murphy, 2011), doubly-robust O-learning replaces R by a doubly-robust
augmented residual of R−E(R|X) (Liu et al., 2018), and M-learning uses R subtract the averaged
outcomes from matched subjects who receive opposite treatment as the weight (Wu et al., 2019).
For the surrogate loss function, both doubly-robust O-learning and M-learning use the hinge-loss
to replace the zero-one loss in Vn(D).
3.2.2 Domain adaptation to improve learning ITRs
Now suppose that in addition to the RCT, we also observe the data from patients in the EHRs, which
include feature variables, received treatments, and outcomes. Our goal is to extract information
from the EHR data to be included in learning the optimal ITR from the trial data. We refer
this information extraction as “domain adaptation” from EHR to the RCT and this framework is
illustrated in Figure 3.1.
Due to the presence of unmeasured confounding in EHRs, we cannot directly learn the optimal
ITR from the combined EHR and RCT data. Instead, we pre-train useful feature mappings from
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EHRs to augment the feature space of RCT. Since physicians’ treatment decisions documented
in the EHRs are likely to carry clinical insights and deemed to be beneficial to a patient among
available options, they are likely closer to being optimal than random assignments (as in RCT).
Thus, features that can summarize physicians’ prescription patterns are informative of the optimal
treatment for a patient. Furthermore, because physicians may prescribe a treatment based on
many considerations including efficacy, risk of complications and cost, their prescription patterns
may not be sufficient when the goal is to learn an ITR to maximize efficacy. The observed benefit
under the optimal treatment in the EHRs captured by an efficacy outcome similar to RCT is also
useful.
Therefore, in the first step of domain adaptation, we capture additional information available
in the EHRs but not in the RCTs (i.e., a physician’s judgment of beneficial treatment and patient’s
observed benefits). We create feature mappings predictive of optimal ITRs and observed benefits
referred to as “super” features. Specifically, we pre-train an ITR to determine each EHR patient’s
optimal treatment by machine learning algorithms described in Section 3.3. The first super feature
is an optimal treatment propensity measure denoted as H1, defined as the probability that a
physician prescribes a particular treatment a0 as the most beneficial choice estimated from all
EHR patients who have received optimal treatments predicted by an algorithm (either predicted
optimal is a0 or −a0). This variable captures the concordance between clinician-based optimal
treatment assignment documented in the EHRs and algorithm-based optimal treatment computed
by the ITRs. To construct this feature, we learn an ITR using a common set of features in EHR and
RCT, say, Xc and methods in Section 3.3. Next, we fit a classification model (e.g., by random forest
classifier or logistic regression) to estimate the probability of a0 being optimal given Xc among the
subset of EHR patients who received optimal treatments as predicted by the ITRs. For information
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transfer, we apply the fitted model to RCT patients and obtain their predicted optimal treatment
propensity measure as the first super feature.
The second super feature is a benefit feature (denoted as H2), which measures EHR patient’s
observed gain or loss on an outcome under the optimal treatment. That is, H2 is the expected
difference in outcome when a subject receives the optimal treatment compared to non-optimal
treatment. To obtain H2, we first fit a random forest regression model for outcomes under optimal
treatment to estimate E(R|A = a∗, Xc) = m1(Xc), using the subset of EHR patients who received
the optimal treatments a∗. Similarly, we fit a model for outcomes under non-optimal treatment,
E(R|A = −a∗, Xc) = m2(Xc), using subjects who received non-optimal treatments. The second
super feature is the predicted benefit H2 = m̂1(Xc)− m̂2(Xc).
In the second step of domain adaptation learning, we estimate the final optimal ITRs from RCT
patients in the augmented feature space (original RCT features and EHR super features H). One
approach is to learn optimal ITRs using the combined features from (H1, H2) and X. However,
directly including super features into the feature set and using the same tuning parameter in the
ITR learning may not distinguish their importance from the original RCT features so may weaken
their effects. To amplify the signals of the super features, we can treat them separately as important
predictive variables through stratification. More specifically, using one of the super features or both
to stratify patients into multiple strata, we learn optimal ITRs separately within each stratum.
The procedure of our method can be summarized in Algorithm 1.
The algorithms (Q-learning and M-learning) to learning the ITRs in RCT and EHR are de-
scribed in Section 3.3.
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Algorithm 1 The Algorithm for Domain Adaptation Learning
Step 0. Use machine learning methods (Q-learning or M-learning) in Section 3.3 to pre-train ITRs
from EHR patients to predict optimal treatment with common features Xc available in RCT and
EHR.
Step 1. Construct H1 and H2 from EHR patients by:
1a. Learn H1 = P (A = a0|Xc) by random forest classification among EHR patients who
received optimal treatments predicted by ITRs obtained in Step 0, where a0 is a pre-specified
treatment.
1b. Learn H2 = E(R|A = a∗, Xc) − E(R|A = −a∗, Xc) using random forest regression
separately for EHR patients who received optimal treatments and non-optimal treatments,
where a∗ denotes the optimal treatment predicted by ITRs in Step 0.
1c. Predict H1, H2 on RCT patients.
Step 2. Learn final ITRs from RCT using algorithms in Section 3.3 by:
1. using all RCT subjects and features (X,H1, H2); OR
2. stratify RCT subjects by H1 and/or H2 and learn separate ITR in each strata.
3.2.3 Justification of domain adaptation learning








where R̃ is the surrogate outcome for R depending on which learning method is used. Note that
R̃ = E[R|A = 1, X,H] − E[R|A = −1, X,H] in Q-learning, R̃ = R in the original O-learning,
R̃ = R−E[R|X,H] in an augmented doubly-robust O-learning, and it is R(a)−E[R|A = −a,X,H]
in M-learning where a is the treatment actually received. Correspondingly, let D̂∗ be the estimated
ITR using empirical data as given in the chapter. Let D0 be the optimal ITR that maximizes
E[ŘI(A = D(X))/π(A,X)] without super features, where Ř is similar to R̃ except that the former
is calculated without stratifying by H but the latter with, and let D̂0 be its estimator.
Case I. When there is no structural assumption on D(x), since H is a function of X, it is clear






































Figure 3.1: Schematics of Proposed Domain Adaptation from EHR to RCT
that D∗(x) maximizes V (D). Thus, both D∗(x) and D0 yield the same optimal rule. Furthermore,
following the same derivation as in (Liu et al., 2018), we have
V (D̂∗)− V (D∗) ≤ (ER̃2)αan + bn
and
V (D̂0)− V (D∗) ≤ (EŘ2)αan + bn,
where α is a constant depending on the underlying distribution and the dimension of X, and an
and bn are constants depending on n and the geometric noise index in the underlying distribution.
Since R̃ is obtained and centered in each stratum but Ř is not, we expect
ER̃2 ≤ EŘ2,
and we conclude that the domain adaptation ITR, D̂∗ leads to a more efficient value than the ITR
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without H. In addition, when H is more predictive of R, which is likely to hold since H contains
the predictive benefit feature H2 using the EHR data, more efficiency is expected when using the
domain adaptation ITR.
Case II. Suppose that there is a structural assumption on D(x), for instance D(x) is linear when
learning ITRs. Since the domain adaptation ITR is learned in each stratum of H, the class of ITRs
considered in the domain adaptation learning is a stratified (piece-wise) linear rule which is broader
than the non-stratified rules. We thus conclude V (D∗) ≥ V (D0). Furthermore, if the treatment
benefit is more heterogeneous across H, which likely holds because H contains H2, then the gain
of the value from the domain adaptation ITR is even more significant.
Case III. Consider that some structural assumption is placed on the ITRs, for example, linear in









where R(1) and R(−1) denote the potential outcomes for treatment 1 and −1 in the trial population,
respectively. In the EHR population, the treatments may act similarly in terms of qualitative effects
(sign of the treatment effect), but the magnitude of the treatment effects (benefits) may not be
as large as what is seen in the trial population which is well managed and performed under ideal
conditions. As such, it is reasonable to assume that the potential outcomes for the EHR population,






where g(X) > 0 and it reflects the heterogeneous ratios of the treatment effects across subgroups
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On the other hand, the EHR super features, H, are highly associated with the treatment effects
in the EHR population. That is, g(X) is highly correlated with H. We conclude that the domain









In other words, the domain adaptation rule leads to an approximately best linear rule maximizing
the value as if treatment outcomes were obtained from the EHR population. In contrast, without










We note that such a rule is not only driven by the treatment effects in the EHR population, but
also depends on the magnitude of g(X). For example, if some group has a large g(X), the optimal
rule D0 is likely to be the optimal linear rule for this particular group but not generalizable to
others. We conclude that domain adaptation ITRs are more generalizable to the EHR population
than ITR from RCT features alone. In summary, we obtain the following conclusions:
(1) If ITRs are learned nonparametrically, the domain adaptation rule leads to the optimal treat-
ment rule with a more efficient value estimation as compared to the optimal rule without the EHR
super features H.
(2) If ITRs are learned in some restrictive class (e.g., linear rules), the domain adaptation rule
always leads to a higher value than the one without H; moreover, it can be more generalizable to
the EHR population when this population has different magnitudes of treatment effects compared
to the trial population.
Remarks: The above conclusion (1) shows that since H are constructed from common features
in RCT and EHR, if the ITRs are learned nonparametrically from RCTs, we may not expect to
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obtain a higher value function than not using H (especially with a large sample). However, by
carefully constructing H to be predictive of optimal rules and observed outcomes from an external
source (EHRs), the precision of value estimation can be improved. Moreover, from conclusions (2)
and (3), when estimating parametric ITRs, including H will lead to a higher value and precision,
and a greater generalizability (under assumptions).
3.3 Algorithms for Estimating ITRs
In Algorithm 1, the pre-training step 0 and the final stratified learning step 2 require some method
to estimate the optimal ITRs. In this section, we describe two learning algorithms that are imple-
mented in our numeric studies.
The first learning algorithm is Q-learning, one of the popular methods for estimating ITRs. We
first fit a predictive model (e.g., random forest regression) with R as output and A and X as inputs.
Next, the optimal treatment is selected as a∗ = arg max{a=1,−1} f̂(X, a) where f̂ is the predicted
mean of R.
The second learning algorithm is M-learning (Wu et al., 2019) with an improvement we develop
in this work. This choice of algorithm is based on the fact that it is a general method including O-
learning as a special case. In this method, a matching function is introduced to estimate individual
treatment responses under alternative treatment assignment. Furthermore, doubly-robust matching
through using prognostic scores in M-learning can further improve efficiency of ITR estimation and
it is expected to perform better especially when the treatment assignment is imbalanced as often
for observational studies. In the original work (Wu et al., 2019), the matched set can be empty; to
avoid this situation, we modify their approach by introducing a soft-matching method, where all
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possible pairs are used but weighted differently according to their feature similarities or prognostic
scores. More specifically, in matched learning (Wu et al., 2019), the value function is re-expressed








I{Rj ≥ Ri,D(Xi) = −Ai}
+I{Rj ≤ Ri,D(Xi) = Ai}
]
u(|Rj −Ri|), (3.3)
where Mi is a matching set for subject i that consists of subjects with similar covariates defined
under a suitable distance metric but opposite treatments. The function u(·) is a monotonically
increasing function to weight different subjects’ outcomes and in our implementation, we choose
u(x) = x. The rationale of (3.3) is that for two subjects who are matched in confounders or
propensity scores of treatments but are observed to receive different treatments, the subject with
a higher outcome should be more likely to have received the optimal treatment. Equivalently, the







I(f(Xi)Aisign(Rj −Ri) ≤ 0)|Rj −Ri|.
A disadvantage of the above matching function is that only a limited number of pairs of subjects
are used. To improve this limitation while accounting for dissimilarity in confounding variables of
subject pairs measured by a suitable distance (e.g., Euclidean or Mahalanobis distance in the feature







I(Ai 6= Aj)kan{s(Xi, Xj)}
I{f(Xi)Aisign(Rj −Ri) ≥ 0}u(|Rj −Ri|), (3.4)
where kan(·) is a kernel function with bandwidth an. For example, with Gaussian kernel kan{s(Xi, Xj)} =
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exp(−an‖Xi, Xj‖2), where ‖ · ‖ denotes some suitable distance function. Note that in (3.4), subject
pairs with different treatments and more similar feature variables or confounding variables and
larger difference in clinical outcomes will receive higher weights. Kernel M-learning thus extracts
information from all possible pairs but adjusts their contribution to the objective function based
on their similarity in confounding variables and differences in clinical outcomes. To solve the opti-
mization problem based on Vn(f) in (3.4), one can replace the zero-one loss by other surrogate loss
function. Specifically, when replacing by the hinge-loss, the optimization problem is transformed








kan{s(Xi, Xj)}u(|Rj −Ri|) + λn‖f‖XK , (3.5)
where φ(x) = (1 − x)+, λn is a tuning parameter and XK is a reproducing kernel Hilbert
space (RKHS) with kernel function K(·, ·). The dual problem of (3.5) is a quadratic programming
problem which can be solved by quadratic programming packages (e.g., through a weighted SVM
with matched pairs) similar to (Wu et al., 2019).
We describe solution to the quadratic problem of weighted SVM for kernel-weighted pairs in
(3.5) using Lagrange multipliers and take linear ITR decision rules as an example. Assume f is
linear in Vn(f) and f(x) = 〈β, x〉 + β0 where 〈·, ·〉 denotes the inner product operator and ‖f‖XK









kan{s(Xi, Xj)}u(|Rj −Ri|)ξij ,
subject to: Aisign(Ri −Rj)(〈β,Xi〉+ β0) ≥ (1− ξij), ξij ≥ 0,∀i and j ∈ {j : Ai 6= Aj},
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where C is a “cost” parameter, ξij is a slack variable that denotes a small portion of misclassification
error for the jth subject which is matched with the ith subject and kan{s(Xi, Xj)}u(|Rj − Ri|) is
the sample weight in a SVM framework (Wu et al., 2019).




















where we minimize with respect to β, β0 and ξij . By taking the respective derivatives and setting










{j:Ai 6=Aj} αijAisign(Ri −Rj),
αij = Ckan{s(Xi, Xj)}u(|Rj −Ri|)− µij , ∀i and j ∈ {j : Ai 6= Aj}.






















{j:Ai 6=Aj} αijAisign(Ri − Rj) = 0.
In addition, subject to Karush-Kuhn-Tucker conditions for ∀i and j ∈ {j : Ai 6= Aj} (Zhao et al.,
2012): 
αij [Aisign(Ri −Rj)(XTi β + β0)− (1− ξij)] = 0,
µijξij = 0,
Aisign(Ri −Rj)(XTi β + β0)− (1− ξij) ≥ 0,
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the solution to the primal and dual problem is optimal. It is not difficult to extend the solution
using other kernels (e.g., Gaussian kernel) and obtain a nonparametric ITR decision rule based on
kernel function K(·, ·) in the RKHS.
3.4 Simulation Studies
In this section, we generated two separate domains of data source to mimic a scenario involving
data from both an RCT and EHR. To accommodate treatment benefit heterogeneity across patient
populations observed in real-world data, we considered the underlying true optimal ITR with a
piece-wise linear tree structure. Specifically, outcome data were simulated as
C1 : R = η(X) + φ(X) ∗A+ ε, ε ∼ N(0, 0.25),
where φ(X) = 0.5I(X1 +X2 > 0)− 0.5I(X1 +X2 <= 0)[1 + I(X2 <= −0.5)] +X23 −X22 , feature
variables Xk were generated from a standard normal distribution, and η(X) = X1 − 0.5X2. Here,
η(X) is the main effect, and the sign of φ(X) defines the true optimal ITR. The true treatment
propensity model in the observational study was specified as P (A = 1|X) = expit(1 + 2X1 + X2)
and the treatment assignment probability for RCT was 0.5.
To accommodate heterogeneity between RCT and EHR patients and unobserved tailoring vari-
able, we considered two scenarios:
(i) All features are observed but X1 has a different distribution in RCT where X1 is restricted to
[−0.4, 0.4];
(ii) Same as (i) but with an additional feature variable X3 as an unobserved tailoring.
Scenarios (i) and (ii) mimic randomized trials where subjects are recruited from subpopulations un-
der certain restrictive inclusion criteria, while the EHR data represent the more general real-world
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patient population.
We compared four strategies of learning ITRs, one using RCT information alone and three
domain adaptation learning:
(S1) Using RCT data and RCT features only;
(S2) Augment the RCT feature set by EHR super features H1, H2 (section 2.2);
(S3) Include H1 in the feature set and stratify by H2;
(S4) Include H2 in the feature set and stratify by H1.
The super feature H1 was estimated from a random forest classification model and H2 from
a random forest regression model. To speed up computation, the tuning parameter an in kernel
M-learning was chosen so that the matched pairs with distance less than an was fixed to be a
proportion of pairs (e.g., 25%) (Liu et al., 2017). In S3, we stratified the training dataset and
testing set based on a median split of the average predicted benefit H2 and included H1 as an extra
feature variable in learning ITR. Similarly, in S4, we stratified the data by the predicted optimal
probability H1 (median split) and included H2 as an additional feature. We considered stratifying
by both H1 and H2 in a simulation in Appendix B.
Q-learning and kernel M-learning were performed under each strategy. In Q-learning, linear
regression was used to fit the linear rule and random forest regression was used to fit the nonpara-
metric rule. In M-learning, weighted SVM with a linear kernel or Gaussian kernel was used. The
tuning parameters for the latter (e.g., cost parameter, bandwidth for Gaussian kernel) were selected
by two-fold cross validation. The value function of the estimated optimal rule was computed on a
large independent testing set (sample size of 10, 000) generated from the general population (EHR)
without restricting X1 or restricted population (RCT) while other procedures remain the same.
We repeated the simulations 100 times.
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Simulation results for M-learning with fitted nonparametric ITRs evaluated on both general
(red) and restricted testing population (blue) are summarized in Figure 3.2. The optimal empirical
value function is 1.48. When testing on the general population, adding super features directly
reduces variability in scenario (i) and also improves value to 1.26 from the original value of 1.10.
Domain adaptation by stratification also performs better than without considering super features
in both (i) and (ii), which is consistent with our theoretical justification given in Section 3.2.3 (Case
I). When testing on the restricted distribution (RCT), adding super features directly achieves the
highest mean value in both scenarios (i) and (ii) (Figure 2a and 2b). The value functions evaluated
on the general population are lower than the restricted population, demonstrating that optimal rule
fitted from the restricted RCT population may not achieve the same effect in the general population.
However, the difference between populations is smaller for the domain adaptation rules, showing
that they may be more generalizable.
In another set of analyses, we fitted linear rules to scenarios (i) and (ii), which are misspecified in
these settings since the true underlying optimal decision function has a piece-wise linear structure.
The results are summarized in Figure 3.2c and 3.2d. Both stratification methods lead to a large
improvement in scenario (i), demonstrating our theoretical justification in Section 3.2.3 (Case
II). Furthermore, domain adaptation rules reach a similar value on the general testing (EHR)
population and restricted (RCT) population. Thus, we show that even though domain adaptation
rules are fitted from RCT population, they behave as if learned from the general population with a
better generalizability. This is consistent with our theoretical justification that domain adaptation
learning is more generalizable due to that super features are highly correlated with the optimal
EHR rules (Section 3.2.3, Case III). The results for Q-learning show similar trends (Appendix B.1).
Additional simulation results for kernel M-learning under presence of unmeasured confounders are
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(d) Scenario (ii), linear rule
Figure 3.2: Simulation Comparisons for M-learning (evaluated on independent testing sets gen-
erated from general or restricted population; scenario (i) has no latent tailoring variables while
scenario (ii) has a latent tailoring variable not used in learning)
To summarize, domain adaptation learning assisted by EHR super features (by directly includ-
ing H or stratifying by H) improves performance of ITR estimation (a higher value or a smaller
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variability). The improvement is observed when evaluated both on the general population and re-
stricted population. The difference of value between populations is smaller with domain adaptation
than without. The simulations suggest that the information gained from EHR may be transferred
to ITR estimation on the RCT data.
3.5 Applications
3.5.1 Motivating Studies
Our research goal is to optimize insulin therapy for T2D patients based on their individual char-
acteristics from RCT data assisted by real-world clinical practices documented in the EHRs. A
randomized controlled trial, DURABLE, was conducted to compare insulin lispro mix 75/25 (fast-
acting medication) versus insulin glargine (Fahrbach et al., 2008). Over 2, 000 patients were enrolled
in this study from 11 countries between 2005 and 2007. The study was designed to compare safety
and efficacy of two insulin types with a 6-month initiation phase. There were 965 patients ran-
domized to lispro mix and 980 patients to insulin glargine. The primary outcome was hemoglobin
A1C (HbA1c) reduction at the end of study (1 year post treatment) and the enrolled patients had
a median baseline HbA1C of 8.8% (Fahrbach et al., 2008).
In recent years, the use of EHRs is continuously growing among clinical researchers with ac-
cess to large-scale clinical data warehouses and databases (Weiskopf and Weng, 2013). and the
EHR warehouses contain massive information that can be used to assist researchers with medical
decision making (Weiskopf and Weng, 2013). For example, EHRs were used to construct ITRs
from real-world patients (Wang et al., 2016). In this chapter, we extracted EHRs from T2D pa-
tients at New York Presbyterian Hospital (NYPH) clinical data warehouse (CDW). The CDW has
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implemented a well-defined quality control process and studies were launched to investigate data
quality including completeness, correctness, concordance, plausibility, and currency (Weiskopf and
Weng, 2013). Recent EHRs in NYPH CDW were used to learn treatment pathways of various
common diseases including T2D (Hripcsak et al., 2016). The main information contained in the
CDW includes demographics, in-patient and out-patient medication prescriptions, ICD diagnosis
codes and laboratory tests, which are longitudinally documented (Wu et al., 2019).
Subjects were included in the EHR analysis if they had insulin aspart or insulin glargine, and
had at least one observation during one year follow up period post insulin initiation. Literature
reveals insulin aspart and insulin lispro are two comparable rapid-acting analogs with similar profile
which have a shorter duration of action, while insulin glargine is a long-acting medication (Plank
et al., 2002; Raja-Khan et al., 2007). In the EHR data, there were 1, 741 T2D patients on long-
acting insulin glargine and 1, 016 on fast-acting insulin aspart. In domain adaptation, we aim to
borrow information from super features on the optimal treatment strategies between two treatments
(insulin aspart vs. insulin glargine) learned from EHR patients and apply to RCT patients to
improve estimation of ITRs. The RCT data are the primary source for learning ITRs to maintain
consistency of the optimal rule due to the virtue of randomization, while EHRs are auxiliary
information to improve efficiency and accuracy of the ITR learning.
3.5.2 Analysis Results
We applied four strategies S1 - S4 as examined by simulations. Our goal was to estimate an
optimal ITR to select the best second-line T2D treatment (lispro mix vs. insulin glargine). The
outcome measure was reduction in HbA1c level 12 months post insulin initiation. Baseline features
extracted from EHRs include age, gender, race, baseline value and rate of change of HbA1c, glucose,
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SBP, DBP, and BMI estimated from a linear mixed effects model. When creating super features
from the EHR, we used inverse probability weighting (IPW) to adjust for missing outcomes. The
weights were obtained by a logistic regression predicting whether a subject had any post insulin
treatment HbA1c measure. For kernel M-learning, baseline and rate of change of lab test values
and demographics variables were used in creating the matching set.
To explore information available in features from two data sources, in Figure 3.3 we present
the t-Distributed Stochastic Neighbor Embedding (t-SNE) to visualize the feature space. The left
panel shows two dimensional features embedded from t-SNE for EHR patients. The embedded
features show a large overlap between the individuals who received different treatments in both
dimensions. Higher dimensional t-SNE figures suggest similar overlap. Therefore, most subjects
in the EHR can find matched neighbors based on their feature variables for M-learning and few
extreme subjects are present. There is small subgroup of patients who received glargine clustered
in the bottom of the figure. Correctly learning ITRs for these subjects will be useful in information
transfer. The right panel shows two-dimensional features embedded for RCT dataset, labeled by
the median split of prognostic scores estimated from a linear regression model fitted under insulin
glargine group. The red dots represent subjects in high prognostic score group (larger than median)
while blue stars represent subjects in low prognostic score group. Although there is some overlap,
two groups clearly separate into two centers. This suggests that RCT features have some power
in predicting prognostic scores and matching on prognostic scores or include them in the learning
step of ITR estimation could improve efficiency.
When pre-training super features on the EHRs, Q-learning was fitted by random forest regres-
sion while kernel M-learning was performed using weighted SVM and tuning parameters (including
choice of kernel as linear or Gaussian) were chosen from the whole sample. In the next step, we
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Figure 3.3: t-SNE Plot for Features Extracted from CUMC EHRs and DURABLE trial
trained random forest models with inverse propensity weighting on the subgroup of patients who
received the optimal or non-optimal treatment assignment according to the estimated ITRs. The
features included in the models were common subset of baseline features in EHR and RCT cohort
including baseline HbA1c, glucose, SBP, DBP and BMI. Furthermore, we used the trained models
to predict two EHR-defined super features on each RCT subject: predicted probability of lispro
mix being optimal for an individual (H1) and predicted benefit under the optimal treatment (H2).
To shed light on the available information from the EHR-derived super features, Figure 3.4
displays t-SNE embedding of RCT features labeled by dichotomized EHR super features. In the
top panel, subjects cluster into two groups based on the dichotomized optimal benefit (H2) and
optimal probability (H1) features, suggesting likely information gain in estimating ITRs if stratified
by these features. In the lower left panel, embedded RCT features can slightly separate HbA1c
reduction as the treatment outcome. On the lower right panel, adding the EHR-derived probability
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feature (H1), more subjects are further separated in terms of treatment outcome, which suggests
optimal treatment probabilities are informative (“high, optimal” represents RCT patients who
received the EHR-predicted optimal treatment and had high HbA1c reduction; “low, non-optimal”
represents RCT patients who received the EHR-predicted non-optimal treatment and had low
HbA1c reduction).
There were 18 baseline covariates in the RCT cohort along with EHR super features included
to estimate ITRs from 1, 945 patients in the RCT. All covariates were standardized before fitting
the model and the empirical value function of A1c reduction was estimated by 100 times of 3-fold
cross-validation. In strategy S2, Q-learning included super features as additional features and M-
learning included them in matching in addition to a prognostic score. In S3 and S4, the RCT
sample was stratified by one of the two super features and the other was included in the learning
or matching step.
The results are displayed in Table B.1 and Figure 3.5. For the non-personalized universal rules,
HbA1c reduction is 1.827 in those assigned with lispro and 1.672 for glargine. Q-learning does
not provide much improvement compared to the universal rule of lispro and directly incorporating
super features barely helps. In S3 when stratifying by benefit feature, Q-learning tends to have
a higher empirical value but also much increased variance. In S4 stratifying by probability, Q-
learning has a higher value. Kernel M-learning achieves a more significant A1c reduction compared
to Q-learning when including super features directly with a mean value function of 1.836. In
M-learning, both stratification methods (S3 and S4) further improve the mean value function. In
particular, stratifying by probability provides a large improvement with a mean value of 1.849. This
suggests that incorporating EHR-derived super features transfer some useful qualitative information
(optimal treatment probability) to improve performance of ITR estimation in the RCT data source.
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Figure 3.4: t-SNE Plot for Features of a DURABLE trial
The increased variability of value function stratifying by probability is partially due to a higher
within-group variability for subgroups defined by probability than by benefit for several important
covariates (e.g. baseline HbA1c, baseline glucose).
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Furthermore, we compared our results with applying ITRs learned from EHR directly on the
RCT data. In Q-learning, this strategy is worse than the universal rule of assigning all to insulin
glargine. In M-learning, the estimated value function was only around 1.7, which is between the





































S1: RCT features only 
S2: Add two EHR-derived features 
S3: Stratyfing by EHR-derived benefit 
S4: Stratyfing by EHR-derived probability 
Figure 3.5: Empirical Value Function of A1c Reduction in DURABLE Trial with 100 3-fold Cross-
validations
Table 3.1: HbA1c Reduction Comparing domain adaptation Learnings on DURABLE Trial (100
repetitions of 3-fold cross-validation)
One-Size-Fits-All: Lispro: 1.827, Glargine: 1.672
Q-Learning Kernel M-Learning
Strategy∗ Mean (Std) Median Mean (Std) Median
S1 1.828 (0.002) 1.827 1.831 (0.004) 1.830
S2 1.828 (0.002) 1.827 1.836 (0.006) 1.834
S3 1.835 (0.010) 1.832 1.840 (0.008) 1.838
S4 1.830 (0.009) 1.832 1.849 (0.011) 1.849
∗: S1: RCT features only; S2: Augment RCT feature set by two EHR data-derived super features H1, H2; S3: Include
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H1 in the feature set and stratify by H2; S4: Include H2 in the feature set and stratify by H1.
In conclusion, domain adaptation learning contributes to transfer informative feature variables
extracted from EHR domain to RCT domain. Among two super features, stratifying by the qualita-
tive probability feature and including the benefit feature in the covariate set improves performance
more than stratifying by the benefit feature. In contrast, we demonstrated that direct applying
fitted ITRs from EHR on RCT does not necessarily lead to a better value function.
3.6 Discussion
In this chapter, we propose domain adaptation learning to transfer information from observational
studies to randomized experiments. In the framework, super features are pre-trained from EHR
database to carry information and achieve domain adaptation to randomized trials. The probability
feature is shown to be more robust than the benefit feature on the real-world EHRs, since it is
more difficult to estimate benefit of the optimal treatment than assessing direction of treatments
in subgroups. To obtain an efficient benefit feature, other approaches for estimating the contrast
function can also be used (Tian et al., 2014). To further improve performance of domain adaptation,
one may consider iteratively deriving informative features from RCT, validate on EHR and vice
versa.
Our method provides performance gain when the super features learned from EHRs are infor-
mative of treatment responses in RCT. In real-world practice, valuable but unobserved tailoring
variables informative of optimal treatment for real-world patients (e.g., clinician’s insights and ob-
servations on patients) may be present and correlate with observed features in the EHRs. Thus,
EHR super features fitted with observed variables may be informative of these latent factors and
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also predictive of the optimal treatment. The higher this correlation, the more gain on efficiency
and generalizability is expected for domain adaptation learning (e.g., Section 2.3). When the EHR
treatments are not beneficial, our approach may not provide gain in efficiency but still remains
consistent (converges to the true optimal treatment rule) because only RCT data are used for
treatment rule learning. In this case, one may consider subgroups in EHRs for which the ITRs are
beneficial.
The proposed pre-training in step 1 of the Algorithm 1 uses the same pre-treatment covariates
in EHRs and RCT. Thus, one consideration of a good EHR/RCT pair to apply our method is the
breadth of features captured in the EHR. Another consideration is the similar direction of treatment
response in subgroups of two populations. While our work focuses on analysis of existing data, it
can be conjectured to use EHR information when designing future RCTs, for example, recruiting
patients from EHRs (Fraser et al., 2012).
Currently we only considered efficacy outcomes. It is desirable to better extract rich information
on other types of outcomes available in the EHRs (e.g., adverse events and long term outcomes)
to further improve ITRs fitted from the RCT. For example, clinicians prescribing treatments in
real-world practice naturally take into account of both efficacy and risk of complications (Wang
et al., 2018). Training ITRs to mimic this behavior would be beneficial. It is also worthwhile to
examine advanced machine learning techniques to explore other features in the EHRs predictive
of treatment prescriptions (e.g, text mining of physicians’ notes), and consider dynamic treatment
rules with longitudinal records.
The proposed domain adaptation framework is easy to implement in practice by following
three steps in Algorithm 1. The main computational burden is on the analysis of the EHR using
matching-based kernel weighting method, since one needs to create a large number of matched
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pairs and fit weighted support vector machines with many matched pairs. When sample size is
large, kernel weighting matching can be replaced by one-to-one matching (Wu et al., 2019). Lastly,
one limitation of the current method is that when super features are less predictive of optimal
treatment or benefit, stratification in domain adaptation learning may lose power. A more data
adaptive framework to treat super features may be investigated (e.g., tuning the number of strata).




Rule Using Topic Modeling Features
4.1 Overview
Personalized treatment decision making has been proposed as a paradigm shift from the universal,
“one-size-fits-all” strategy (Collins and Varmus, 2015) to address substantial heterogeneity between
patients affected by chronic disorders such as type 2 diabetes (T2D) and mental disorders (Fried
and Nesse, 2015). Recently, personalized medicine research is fast growing and greatly facilitated by
large-scale data collection and technological advances in data storage and processing (Collins and
Varmus, 2015). Personalized medicine allows healthcare providers to tailor treatment or treatment
sequences to individual patient accounting for personalized information and patient heterogeneity
(Chakraborty and Moodie, 2013).
One way to personalize medicine is to prescribe treatment using individualized treatment rules
(ITRs) which are mappings from a patient’s feature space (e.g., biomarkers of patient’s health
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status) to the space of potential treatment decisions. Randomized controlled trials (RCTs) are
considered to be of high internal validity due to the virtue of randomizing treatments so that RCTs
are not subject to unmeasured confounding. However, due to their stringent inclusion and exclusion
criteria, RCTs lack generalizability or external validity to a broader and diversified population (Cole
and Stuart, 2010). Studies comparing T2D patient population in EHRs and participants of RCTs
for T2D found a large difference in their distributions (Weng et al., 2014). In contrast, EHRs provide
a complementary resource for learning ITRs in a large real world patient population. Recently, large
scale EHR data has been leveraged to characterize treatment pathways in medical decision making
(Hripcsak et al., 2016). Due to the non-experimental characteristics in retrospectively documented
observational data, it is difficult to infer causality or valid ITRs without employing confounding
and selection bias reduction techniques (Rosenbaum, 2010; Wang et al., 2016). It is beneficial
to integrate medical domain knowledge in feature engineering with valid machine learning and
statistical methods in alleviating biases to better estimate optimal decision rule in observational
studies.
Machine learning methods are commonly used to optimize treatment decisions by estimating
ITRs according to patient level feature variables. Indirect methods such as Q-learning (Watkins
and Dayan, 1992; Qian and Murphy, 2011) and A-learning (Murphy, 2003) fit a regression model
to predict clinical outcome under alternative treatments and derive optimal ITRs by comparing
predicted outcomes. Such methods are subject to model misspecification. Alternatively, outcome
weighted learning (O-learning) and augmented O-learning (Zhao et al., 2012; Liu et al., 2018) are
proposed to directly maximize clinical outcome after treatment. O-learning converts treatment op-
timization to a classification problem without requiring a model to predict the treatment responses.
Tree-based methods use criteria related to testing for treatment by feature variable interaction effect
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to partition patients (Dusseldorp and Van Mechelen, 2014; Laber and Zhao, 2015). Most of these
methods are suitable for estimating ITRs from RCTs and cannot be directly applied to observa-
tional studies without adjusting for various sources of biases. Recently, a matching-based learning
method referred as M-learning (Wu et al., 2019) is proposed to generalize O-learning methods un-
der a unified framework and can be applicable to EHRs. However, M-learning method does not
optimally engineer feature variables from EHRs.
Topic modeling techniques can be adapted to process text notes or similar text-like information
in EHR data including latent semantic analysis (LSA) (Landauer et al., 1998), probabilistic latent
semantic analysis (pLSA) (Hofmann, 1999). Both methods achieve a lower dimension representation
for text information. In addition, latent Dirichlet allocation (LDA), as a generative statistical
model for collections of discrete type of data, has also been adopted to reduce dimension and data
representation (Blei et al., 2003).
In this chapter, we present analyses methods to estimate optimal individualized treatments
from EHR data with two main goals. The first goal is to achieve more effective feature extraction
for identifying optimal ITRs with EHRs. The extracted features should be predictive in selecting
optimal treatment and interpretable to clinical practitioners. The second goal aims at improv-
ing algorithms for treatment optimization and reducing confounding bias in statistical estimation
especially in real world setting such as EHRs. We will use LDA as a type of topic models to an-
alyze medication and condition domain of EHR data to extract features and apply three learning
methods (Q-learning, O-learning and M-learning) to estimate the optimal ITRs depending on a
patient’s personalized characteristics such as demographics and predictive markers augmented by
LDA-based features. We compare the performance of the three learning algorithms with or with-
out augmenting feature space by LDA-based topic features. Additionally, we investigate important
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LDA-based features to provide the interpretation of ITRs using engineered topics in co-medication
and diagnosis domains. The proposed method has the promise of discovering medical knowledge
from observational data to facilitate individualized medical decision making.
4.2 Methodology
4.2.1 Review of Methods for Personalized Treatment
In this section, we review the basic concept and framework for individualized treatment rule and
three methods in learning treatment rule including Q-learning, O-learning and M-learning methods.
Since M-learning has been shown to be superior to the other two in certain cases in observational
studies and our application in the chapter is in the area of electronic health records, we revisit the
key idea and derivation of M-learning in Chapter 2.
4.2.1.1 Individualized Treatment Rule Framework
An individualized treatment rule (ITR) is a decision function that maps patients’ features into
the space of treatment options. In this chapter, we consider single stage decision rules and binary
treatment options. Extension to multiple treatment options can be achieved using methods in
(Zhou et al., 2018). Let Hi denote the feature variables measured prior to treatment and Ri denote
the clinical outcome or reward post treatment and we can assume a larger Ri corresponds to more
desirable treatment effect (e.g., symptom relief). Let T denotes the treatment assignment taking
values of −1 or 1, and let D(Hi) denote an ITR. The value function used to evaluate an ITR
associated with the decision rule D is defined as the expected post-treatment reward:
V (D) = ED(Ri).
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In particular, when the treatment assignment probability is known in an RCT, the value func-





, where π(t, h) is the
randomization probability for T = t given H = h. In contrast, in an observational study (e.g.
EHR data) treatment propensities π(t, h) are usually unknown and need to be estimated from data
using classification models such as logistic regression or random forest (Lee et al., 2010). The value









Optimal ITRs are estimated from data by maximizing the above empirical value function (4.1).
4.2.1.2 Q-learning and O-learning Methods
There are many machine learning tools to estimate ITRs including Q-learning and O-learning meth-
ods. Q-learning is a reinforcement learning algorithm that plays an important role in estimating
ITRs for multi-stage studies (Qian and Murphy, 2011). In Q-learning methods, regression-based
approach is implemented to approximate R in V (D) by the estimated treatment benefit through a
model R = f̂(H,T ) using H and interactions between H and treatment assignment T as predic-
tors. The optimal ITR selected by Q-learning is expressed as t∗ = maxt∈{1,−1} f̂(H, t) (Wang et al.,
2016). Q-learning indirectly maximizes the value function and may be sensitive to incorrect model
assumptions when feature space is high-dimensional (Zhao et al., 2012; Wang et al., 2016).
O-learning is a class of machine learning methods that directly maximize the expected clinical
reward under a treatment assignment strategy. In the original O-learning, ITR estimation is trans-






(Zhao et al., 2012). Augmented O-learning (AOL) is an improved version
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of O-learning by replacing Ri with a doubly-robust residual of Ri − E[Ri|Hi] (Liu et al., 2018).
Efficiency gain can be guaranteed in the AOL by integrating O-learning with regression-based Q-
learning in a doubly-robust manner (Liu et al., 2018). However, O-learning methods are based on
inverse probability weighting (IPW) of estimated propensities π(Ti, Hi) and may suffer from sev-
eral issues such as instability of weights estimation and imbalance of covariates distribution across
treatment groups (Wu et al., 2019) when applied to observational data.
4.2.1.3 M-learning Method
In this chapter, we focus on M-learning method. M-learning is a matching-based learning method
that also directly maximizes the value function. It generalizes O-learning methods and integrates
them with matching techniques. Specifically, M-learning performs matching to accurately measure
individuals’ treatment responses to alternative treatments, which requires less model specification
and provides more flexibility in controlling confounders in the subgroups (Wu et al., 2019). In
observational studies, π(Ti, Hi) is unknown and confounding bias commonly complicates analyses.
It is well known that IPW-based methods for adjusting for confounding suffer from high variability
especially when weights π(Ti, Hi) are small in subgroups of individuals and lack control over sub-
group propensity score balance (Lee et al., 2011). Thus M-learning that avoids inverse weighting of
π(Ti, Hi) may be more advantageous over IPW-based approaches in the observational studies (Wu
et al., 2019).
The key idea behind M-learning is that when two subjects are matched in terms of confounders
or propensity scores of treatments but receive different treatments, the observed treatment leading
to a larger clinical response should be more likely to be the optimal option. We describe M-learning
method as follows: for any subject i, we first identify a matched setMi, which consists of subjects
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with opposite treatments but similar feature variables as subject i, where similarity is defined under
a suitable distance metric. That is, we let
Mi = {j : Tj = −Ti, d(Hj , Hi) ≤ δi} .









I(Rj ≥ Ri,D(Hi) = −Ti)
+I(Rj ≤ Ri,D(Hi) = Ti)
}
. (4.2)
where |Mi| is the size of the matched set Mi and u(·) is proposed as a monotonically increasing
matching function to weight individual subjects. Common choice of u(·) can be u(x) = 1 or
u(x) = x according to users’ objective. Note that when u(x) = x and we choose one-nearest-
neighbor matching, the value function is weighted by the absolute difference between the clinical
reward in the matched pair, i.e., |Rj −Ri|. Equivalently, value function (4.2) is further written as







u(|Rj −Ri|)I(f(Hi)Tisign(Rj −Ri) ≤ 0), (4.3)
where D(H) = sign(f(H)) for some decision function. To estimate the optimal ITR in (4.3), it is
equivalent to minimize the loss function







u(|Rj −Ri|)I(f(Hi)Tisign(Rj −Ri) ≥ 0). (4.4)
Due to the discontinuity of the indicator function in (4.4), we replace the zero-one loss by
alternative loss function for optimization. In this chapter, we use hinge-loss and the optimization
becomes a weighed support vector machine (SVM) problem for matched pairs:







u(|Rj −Ri|)φ(−f(Hi)Tisign(Rj −Ri)) + λn‖f‖HK . (4.5)
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In Vφ(f ;u), φ(x) = max(1−x, 0), λn is a penalty parameter and HK is a reproducing kernel Hilbert
space (RKHS) with kernel function K(·, ·). The solution to the dual problem of (4.5) using any
off-the-shelf quadratic programming packages leads to the minimization of M-learning.
Additionally, the use of idea in doubly robust matching estimator (DRME) (Antonelli et al.,
2018) can improve M-learning. The DRME incorporates both propensity score and prognostic
score in matching setMi. The propensity score model π(H) and prognostic score model m(H) are
defined as
π(H) = P (T = 1|H) = g1(H ′γ1)
and
m(H) = E(R|A = −1, H) = g2(H ′γ2)
where γ1, γ2 denotes parameters for the two models. This extension in M-learning is doubly robust
and is consistent even if one of the two models is misspecified (Wu et al., 2019).
It has been discussed in (Wu et al., 2019) that original O-learning and single-stage AOL are
special cases of M-learning. Unlike O-learning methods which compare observed reward R with a
constant or predicted outcome, M-learning directly compares observed individual rewards from the
two subjects in the matched set Mi. This demonstrates that M-learning methods have advantage
over O-learning methods in ITR estimation leveraging individual information instead of predicted
outcomes averaged across treatments (Wu et al., 2019).
4.2.2 EHR Data
Before introducing topic model as a method for feature extraction, we briefly review the EHR data
that have been used in this work and the issues we have addressed for the analyses. The EHR
data was collected and stored in a large clinical data warehouse (CDW) at New York Presbyterian
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Hospital (NYPH) which contains over 20 years of health information for about 4.5 million patients
(Johnson, 1996) . There are over 115,000 patients who had been diagnosed with type 2 diabetes
(T2D) (Weng et al., 2014). The quality of the EHR data including completeness, correctness,
and plausibility was investigated to ensure suitability for studying treatment sequence of common
diseases (Weiskopf and Weng, 2013; Fort et al., 2014). Current T2D guidelines suggest metformin
(MET) as the preferred first-line medication (Diabetes Control and Complications Trial Research
Group, 1993), but in the real world setting, there is no recommendation of optimal sequence of
treatments on the long-term outcomes in the literature (Bennett et al., 2011).
In this chapter we propose machine learning methods to estimate the optimal second-line treat-
ment of T2D, specifically, we compare Met + insulin versus Met + sulfonylureas (SFU). To match
this goal, we used a new-user design to select our cohort for analyses. Since our goal is to opti-
mize second-line treatments, we included patients who had a first-line treatment and switched to
a second-line treatment of SFU or insulin during 2008 and 2012. Each subject’s observations are
re-aligned at the time of switching (index time 0). A median baseline period of 12-months prior to
the index time was established to extract baseline feature variables. The median follow-up period
post index time to evaluate treatment response is 18-months. The primary outcome is the num-
ber of major complications of T2D after second-line treatment including essential hypertension,
hyperlipidemia and hypercholesterolemia.
Unlike randomized experiment, EHR data are collected in an uncontrolled setting and pose
challenges for inferring causal relationships in research studies. In our analyses, we address three
major issues commonly confronting observational study research including confounding bias, se-
lection bias and missing data. To alleviate confounding bias, we implement matching step in
M-learning on potential confounders (e.g. lab test features), two propensity scores constructed by
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two logistic regression models for lab measurement pattern features and demographics predictors
and a doubly-robust prognostic score estimated from a linear regression model. To reduce selection
bias due to missing post second-line treatment outcomes, IPW adjustment was implemented and a
logistic regression model was used to predict the presence of at least one post-treatment measure
during the follow up period. Lastly, missing features were imputed with chained equations.
4.2.3 LDA-Based Features for Co-medication and Diagnosis
In this chapter, we extracted clinically meaningful features from two EHR data domains (i.e. med-
ications and ICD diagnosis codes) using latent Dirichlet allocation model (LDA) as a topic model
based approach. LDA is a three-level hierarchical generative model suitable for analyzing collec-
tions of discrete data and has broad applications from information retrieval to medical informatics
(Blei et al., 2003). When applied to EHRs, it can organize a large number of ICD diagnoses codes,
procedure codes and medication prescription documentations into meaningful topics based on the
correlation among variables. As a generative model, LDA is parameterized by distributions over
topics, where each topic is characterized by a distribution over words in that topic. Thus, LDA
models are highly interpretable.
In our EHR analyses, each patient can be viewed as a “document” in topic modeling applica-
tions. LDA model is adapted here to learn the hidden topics in the domain information for the
collection of patients. In the medication prescription domain, the medication items in the generic
name field except the T2D treatments are the “words” in a “patient’s document”. The latent topics
learned in this domain are referred to as co-medication topics. Similarly, the ICD9 codes in the
diagnosis domain are useful terms to learn topics of patient comorbidities. The number of topics
is fixed for the two domains and the latent topics were learned separately.
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Specifically, the key idea of using LDA to analyze medication prescriptions and ICD codes in
EHRs is that the patient population (collection of “documents”) can be represented as mixture of
multiple latent subgroups or topics and each topic is defined to be a multinomial distribution over
a collection of “vocabulary” of medications or conditions (i.e., terms) (Blei et al., 2003; Blei and
Lafferty, 2009). LDA assumes a probabilistic generative process by which each patient is generated
with K latent topics and each topic is assumed to follow a Dirichlet distribution over V medications
or conditions in the “vocabulary”. We describe the process as follows (Blei et al., 2002). Let C
denote a corpus composed of M patients represented as C = {c1, c2, · · · , cM} .
1. For a patient of N medications or conditions, first a distribution over topics is drawn from
θ ∼ Dir(α),






θα1−11 · · · θ
αk−1
k ,
Γ(x) is the Gamma function, 0 < αi < 1,∀i and
∑k
i=1 θi = 1.
2. For each medication or condition of the patient, a topic x ∈ {1, · · · ,K} is drawn from
x ∼ Mult(θ),
where Mult(θ) is a multinomial distribution characterized by θ and p(x = i|θ) = θi.
3. Given the topic, medications or conditions of the patient are drawn from a conditional multi-
nomial distribution p(w|x;φ), where φ is the parameter of the per-topic distribution over
medications or conditions.
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Several Bayesian inference techniques can be used to approximate the posterior distribution
p(θ, x|w,α,φ) = p(θ, x,w|α,φ)
p(w|α,φ)
in LDA including variational inference, expectation propagation and Gibbs sampling (Blei et al.,
2003; Geman and Geman, 1984; Minka and Lafferty, 2002). We can obtain the marginal distribution










and take the product of the marginal probabilities of patients to derive the probability of the corpus
(Blei et al., 2003). In LDA, the Dirichlet is drawn for each patient, and within this patient the
multinomial topic distribution over medication or conditions is drawn repeatedly (Blei et al., 2002).
The weights of posterior probabilities or proportions for different topics given patients’ observed
medications and conditions obtained from Bayesian inference are the feature representation in a
reduced dimension (dimension equals to the number of topics). In our application, both clinical
interpretability and topic coherence measure were taken into consideration and 5 topics were used.
The LDA-based features were constructed based on these weights and they were augmented to the
feature space in our analyses in learning the personalized treatments and confounding reduction.
We compared using LDA-based features with using a simple summary feature of a total number of
medications or ICD diagnoses.
4.3 Applications
In this section, we introduce our cohort identification and EHR preprocessing procedures. LDA
model is used in representing the variables in two data domains in the EHR data in a lower
dimension. The learned topics from the LDA model are visualized and association networks are
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built to better interpret the topics. The features we extracted from the latent topics were augmented
to the feature space in machine learning methods in estimating the ITRs.
4.3.1 Cohort Identification
Our cohort includes patients who were older than 18 years and had at least one T2D diagnosis
between 1/1/2008 and 12/31/2012. The analysis was further restricted to those patients who
were prescribed with Metformin as first-line medication (Wu et al., 2019). There were over 1,200
patients who were augmented with at least one second-line treatment. The sunburst plot in Figure
4.1 displays treatment sequence with 2-3 stages for T2D patients in the database. The most inner
circle corresponds to the first-line treatment and the most commonly used first stage treatment is
Metformin, which is consistent with the T2D treatment guideline. Our goal is to select optimal ITRs
to reduce major complications. The ITRs were estimated in terms of lowering major complications
of T2D measured by three ICD diagnosis counts as ordinal outcomes (0, 1, 2, 3).
The EHR data preprocessing flowchart is shown in Figure C.1. Most features were extracted
from four domains: demographics, medication prescriptions, lab test and diagnosis. Several impor-
tant lab tests (e.g. HbA1c, glucose, HDL, LDL, BMI) were summarized by estimated initial test
values and estimated rate of change using linear mixed effect models. Initial test value is a measure
of patient’s illness condition at the baseline of study and rate of change of test value characterize
patient’s progression rate of disease. Lab measurement pattern features were constructed using
the information in the lab test domain (Wu et al., 2019). Lab measurement patterns in EHRs
were shown to reflect patient’s underlying health status as well as EHR documentation biases and
thus informative of adjusting for confounding and matching patients (Pivovarov et al., 2014). In
Figure C.6, the measurement patterns of glucose test and HbA1c in terms of gap days in logarithm
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Figure 4.1: Sunburst plot of treatment sequence for T2D patients*
*: Layer corresponds to stage of treatment, patients with 2-3 stages were shown
scale is different for patients on different second-line treatments, suggesting it can distinguish be-
tween patients who started insulin (MET+insulin) and those who received glyburide or glipizide
(MET+SFU). In Figure C.7, the measurement patterns of one of clinically important lab mea-
sures HbA1c and medications in terms of gap days in logarithm scale are displayed for different
treatment strategies. The difference in these figures further demonstrates the usefulness of these
measurement patterns in personalized treatment. Therefore the lab measurement pattern features
were used as important predictors for computing a balancing propensity score (Wu et al., 2019) in
M-learning. The features capturing temporal measurement patterns were created by discretizing
a two-dimensional space of lab test values versus gap time between consecutive measurements ac-
cording to high, medium, low quartiles (Wang et al., 2016). Additionally, age, race and gender were
also included as demographic variables for matching patients. Spikeplots for important lab tests
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such as glucose and HbA1c and medications among sample patients are shown in Appendix C.2.
These figures capture patient heterogeneity in terms of measurement pattern of lab and medication.
4.3.2 LDA Feature Representation
Topic model with LDA using bag of words is applied to the generic names in co-medications and
condition ICD9 codes prior to second-line treatment initiation (during baseline period) with 5 la-
tent topics respectively. There were over 700 generic medication names and over 2, 800 unique
ICD9 codes in this T2D EHR data. In the co-medication domain, bigram and trigram were created
for compound words in generic names. The number of topics is fixed in our application for inter-
pretability purposes. LDA-based features were constructed as weights for each of the 5 topics per
patient. We use heatmaps with hierarchical clustering to show topic feature weights in all patients.










where K is the fixed number of topics and θdi,k denotes weight for topic k in each patient. In Figure
4.2a, the heatmap for co-medication topic features suggests that most patients have higher weights
in only one or two topics. Thus, co-medications for most patients comprise of one or two latent
topics. Figure 4.2b shows patterns of ICD diagnosis condition, and a relatively high proportion of
patients have larger weights in the first condition topic, which mainly consists of conditions such
as hypertension, pure hypercholesterolemia, depressive disorder, hyperlipidemia and lumbago.
To understand the learned topics, we present visualization of some of the medication and con-
dition topics in Figure C.3, C.3 and C.3. These topics were found to be informative of predicting
optimal treatments in our subsequent analyses (next section). On the right panel of each sub-figure,
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(b) Condition Topic Features
Figure 4.2: Heatmap of LDA-Features Clustered by Patients
the top 30 most relevant terms (co-medications or conditions) corresponding to the topics are pre-
sented. For example, topic #3 in the co-medication domain is a cluster of medications used to treat
heart disease, high blood pressure and high cholesterol. Figure C.3 shows that this topic contains
5 most relevant prescriptions as aspirin, metoprolol, atorvastatin, enalapril and clopidogrel. In
condition topic #2, the most relevant conditions include hypertension, hypercholesterolem, pain in
limb, atrial fibrillation and hyperlipidemia, which are common co-morbidities of T2D. In condition
topic #5, the top most relevant conditions are benign hypertension, hyperlipidemia, asthma and
obesity.
Based on topics learned from LDA models, we constructed association network for medications
and conditions separately in Figure 4.3 and 4.4. The medications or conditions (nodes in the net-
work) in the same topic with a posterior probability of co-occurring higher than a threshold are
linked by an edge and shown in the figures. The threshold is 1.5% for co-medications and 0.9%
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for conditions for visualization. The edge widths are proportional to posterior probabilities. In
the condition network, mental disorders including anxiety, depressive disorder and schizoaffective
as well as some side effects such as cough, headache and backache are clustered in the rightmost
group. Cardiovascular system related disorders conditions such as old myocardial infarction, mixed
hyperlipidemia, atrial fibrillation and coronary atherosclerosis are connected together in the bot-
tom cluster. Several topic clusters are connected through “bridge conditions/procedures” such as
hypertension, unspecified hyperlipidemia, and flu vaccination which are associated with conditions
in other clusters. In the co-medications network, several anti-diabetic or heart disease medications
are clustered together including Rosuvastatin, Pioglitazone, Warfarin and Sitagliptin. Drugs used
to treat co-morbidities are connected in a group such as Levothyroxine (treat thyroid disease), Es-
omeprazole (treat gastroesophageal reflux disease) and Atenolol (treat high blood pressure and chest
pain). In this co-medications network for T2D, aspirin, as a blood thinner and anti-inflammatory
drug, plays an important role in bridging medications from several clusters since aspirin is often
co-prescribed with other medications.
4.3.3 Learning Optimal ITR
In our final analysis cohort, there were 740 subjects in total. The cohort was further divided
into high baseline HbA1c level group and low baseline HbA1c level group according to median
initial HbA1c level of 8.5% to account for patient heterogeneity. There were 380 patients in the
low baseline group among whom 240 (63%) was prescribed SFU as second-line medication and
140 (37%) was prescribed insulin. In the high baseline group, the number of patients received
SFU and insulin were 208 (58%) and 152 (42%) respectively. The outcome Ri used to minimize
the value function (4.4) is count of post-treatment major complications (essential hypertension,



































































Figure 4.3: Association Network of Medication Prescriptions Based on Topics in LDA Model
hyperlipidemia and hypercholesterolemia) during the follow up period. We performed 2-fold cross-
validation 100 times, and computed the cross-validated empirical value function under three learning
methods (Q-learning, O-learning and M-learning).
In Table 4.1, we present the previous results in (Wu et al., 2019) with the raw counts from co-
medication and diagnosis domain during the baseline period included as feature variables instead
of using LDA-based features. In Table 4.2, we replaced the raw co-medication count and condition
ICD9 codes count with our extracted LDA-based topic features. Comparing this to the results
excluding LDA-based features, all the three learning methods in both groups improve with lower
values of post-treatment major complications counts. In the two groups, most of the methods
result in a smaller variability. In the high baseline group (see Figure 4.5a), the worst performance
learning method using raw count data is Q-learning. It benefited most from including LDA-based
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Figure 4.4: Association Network of ICD9 Conditions Based on Topics in LDA Model
features. In the low baseline group (see Figure 4.5b), M-learning using LDA-based features achieves
the lowest value function with a mean of 0.71 and the standard deviation of 0.028. In Figure 4.5,
we note that all three ITR learning methods outperform the “one-size-fits-all” strategies to assign
insulin to all subjects or SFU to all. This analysis demonstrates that prescribing treatment based
on each patient’s characteristics reduces the number of major complications compared to universal
treatment prescription.
We identify the important topic features for selecting the optimal treatment by implementing M-
learning with linear kernel SVM including LDA-based features in the cohort of 740 patients. There
were 427 (58%) patients predicted to have “MET + SFU” as the optimal second-line medication
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Figure 4.5: Empirical value function of ICD diagnosis count in EHR data with 100 2-fold cross-
validations (a low value is desirable)
Table 4.1: Cross-validated Empirical Value Function for
the Number of Major Complications Using Raw Count
Data
High Baseline Group
ITR Method Mean (Std) Median (Q1, Q3)
Q-Learning 0.88 (0.078) 0.88 (0.83, 0.93)
O-Learning 0.86 (0.050) 0.87 (0.83, 0.90)
M-Learning 0.84 (0.068) 0.83 (0.80, 0.88)
Low Baseline Group
ITR Method Mean (Std) Median (Q1, Q3)
Q-Learning 0.81 (0.063) 0.81 (0.76, 0.85)
O-Learning 0.72 (0.033) 0.72 (0.70, 0.74)
M-Learning 0.73 (0.032) 0.73 (0.71, 0.75)
CHAPTER 4. LEARNING PERSONALIZED TREATMENT RULE USING TOPIC
MODELING FEATURES 95
Table 4.2: Cross-validated Empirical Value Function for
the Number of Major Complications Using LDA Fea-
tures
High Baseline Group
ITR Method Mean (Std) Median (Q1, Q3)
Q-Learning 0.77 (0.065) 0.77 (0.73, 0.81)
O-Learning 0.81 (0.045) 0.81 (0.79, 0.84)
M-Learning 0.83 (0.088) 0.81 (0.78, 0.86)
Low Baseline Group
ITR Method Mean (Std) Median (Q1, Q3)
Q-Learning 0.77 (0.048) 0.77 (0.73, 0.80)
O-Learning 0.72 (0.029) 0.72 (0.70, 0.74)
M-Learning 0.71 (0.028) 0.72 (0.70, 0.73)
and 313 (42%) to have “MET + insulin”. We show the absolute value of all the standardized
coefficients in Figure 4.6. Besides race and cluster membership variable (based on hierarchical
clustering analysis for patient heterogeneity using a subset of standardized features), co-medication
topic #3, condition topic #5 and #2 rank as the most important topic features. The most relevant
terms in these three topics are presented in Appendix C.3. Medication topic #3 involves past
prescriptions of drugs used to treat heart diseases and its risk factors, while condition topic #5
and #2 includes major T2D co-morbidities. These results suggest that to recommend optimal
second-line treatments, physicians may focus on past heart disease mediation prescriptions and
past diagnostic history of hypertension, hypercholesterolem, and atrial fibrillation.















































































































































































Figure 4.6: Feature Importance in M-learning with a Linear Kernel
4.4 Discussion
In this chapter, we investigate topic modeling with LDA as a feature extraction tool for EHR
data and the use of a matching-based machine learning method for individualized treatment op-
timization. The learned features from LDA can be used in the ITR learning step to improve
interpretability of the ITRs. Compared to treatment rules estimated excluding LDA-based fea-
tures, our method achieves better post treatment clinical outcome and a smaller variability. In
addition, LDA-based features summarize a large number of ICD codes and medications into a few
understandable topics. By examining important topics predictive of optimal treatment, our method
provides an intuitive summary of main useful characteristics a physician needs to focus on when
making personalized medical decisions.
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Chapter 5
Conclusions and Future Direction
5.1 Summary
The overall theme of this work is merging statistical modeling and feature engineering techniques
with machine learning algorithms to assist in personalized medical decision making, leveraging the
information from electronic health records.
Chapter 2 considers a matching-based learning method, referred to as M-learning, to learn per-
sonalized treatment rule from observational data. We show its advantage over existing methods
in several scenarios through extensive simulation studies and a real data application using EHR
from diabetes patients. In Chapter 3, we propose a novel framework using a few learning methods
including an extended version of M-learning to transfer information learned from real-world obser-
vational data to RCT. Two super features are used in this framework. We show the efficacy of this
framework through simulation studies and a data application using both EHR and RCT data of
diabetes study. In Chapter 4, a topic model based method is considered to extract interpretable
features from different domains of EHR data and use learning methods to estimate ITRs. We eval-
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uate the benefit gained from this method by comparing to previous methods without augmenting
the topic model based features using EHR from diabetes patients.
5.2 Limitations
In M-learning proposed in Chapter 2, one-nearest-neighbor matching might result in many repeated
observations in the learning step and only a limited number of pairs of subjects are included.
An extension of M-learning, which is proposed in Chapter 3, resolves this by integrating with
kernel method using a kernel weighted objective function for optimizing. However, there is a
tradeoff between accuracy and computational speed. The computation cost of implementing kernel
M-learning is significantly higher without resort to more efficient algorithms or more powerful
computational resources. Another limitation of the transfer learning in Chapter 3 is that when super
features are less informative of optimal treatment or benefit, stratification in domain adaptation
may not work. In Chapter 4, there is no consensus on optimal measure in selecting number of
topics in LDA model and in our case, a fixed number is used based on clinical interpretability and
topic coherence. The original topic model does not consider correlation between latent topics and
the trend in topics change over time. Lastly, we use EHR data from NYPH clinical data warehouse
and do not evaluate the performance of our proposed methods and framework in other databases.
We believe that investigating performance using EHR data from other hospitals will be helpful,
especially in transfer learning framework.
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5.3 Extensions
In Chapter 2, we focus on single-state M-learning and it can be generalize to multi-stage applying
the backward learning techniques. In addition, more general multi-arm treatment options can be
considered. To improve the performance, data-driven oriented matching functions and suitable
matching variables can be selected when applying our method to satisfy both clinical interpretabil-
ity and precision of ITR estimation. In Chapter 3, our proposed super features and framework
is not difficult to implement. However, there is certain computational burden in searching the
optimal parameter space when running the algorithms. In the future direction, more compu-
tational efficient algorithms should be applied. In particular, a mini-batch version of weighted
SVM can be implemented in our kernel M-learning. Additionally, instead of the original super
features, other features predictive of treatment options in observational studies is worthwhile to
be examined. In Chapter 4, several extensions can be considered. It is desirable to consider a
data-driven method to select the best number of topics in LDA-based feature extraction. It is
of interest to investigate a hierarchical, comprehensive LDA-based feature extraction combining
different domains including medications, conditions and procedures altogether instead of modeling
them separately. Moreover, correlated topic models can be considered to model the correlation
between topics within each medical domain and dynamic topic models might be useful in capturing
the temporal characteristics of the evolution of medical concepts. Hierarchical topic models can
also be used to incorporate existing hierarchical structure of medications or diagnosis into learning
topics. With these specific topic models, more meaningful feature representation can be achieved.
Additionally, we can extend nearest-neighbor matching in M-learning to other optimal matching
techniques such as integrating with kernel method. These extensions will provide more flexibility
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to M-learning, especially for observational studies. Lastly, it is worthwhile to extend our methods
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Appendix A
Appendices to Chapter 2
A.1 Additional Simulations Evaluating M-learning for Discrete
Outcomes
In this part, ordinal outcomes were generated by discretizing a latent continuous outcome generated
similarly to those in Chapter 2.4. The underlying continuous outcomes were simulated as
S1 : R = 2H3 −H4 +A(H1 −H2) +N(0, 1)
and
S2 : R = 1 + 2H1 +H2 + 0.5H3 +A(H2 +H
2
1 − 1) +N(0, 1).
Furthermore, R was discretized into an ordinal clinical response outcome with 4 categories based on
quantiles. In section A3, boxplots comparing value functions of M-learning, AOL and Q-learning
under different sample sizes can be found. The true optimal value is 1.11 in S1 and 2.23 in S2.
In the first set of analyses, the distribution of A depended on H and no unmeasured confounder
is present. Propensity model was specified by P (A = 1|H) = expit(1 + 2H1 + H2) and a logistic
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regression with H1 and H2 as linear covariates was used to estimate propensity scores. In the linear
boundary setting, Q-learning ranks the best and M-learning is slightly worse than AOL. In S2,
M-learning is more robust to outliers and hence performs much better than AOL. The difference
of value function between using g(x) = x or g(x) = 1 is negligible.
In the second set of analyses, we specified propensity score model as P (A = 1|H) = expit(1 +
exp(H2)). A logistic regression with H1 and H2 as linear covariates was used to estimate propensity
scores and thus the model is misspecified. In S1, AOL is better than M-learning in terms of value
function and Q-learning still has a higher value. While in S2, AOL performs much worse than
M-learning since AOL is more sensitive to incorrectly specified propensity score model.
In the third set of analyses, we considered presence of unmeasured confounders. The clinical
outcomes were simulated as
S3 : R = 2H3 −H4 +A(H1 −H2 +X) +N(0, 1)
and
S4 : R = 1 + 2H1 +H2 + 0.5H3 +A(H2 +H
2
1 +X − 1) +N(0, 1)
where P (A = 1|H,X) = expit(1 + R(−1) − R(1) + 2X + H1) and X is an unmeasured confounder
(not included in any analysis in any method) and R(−1), R(1) are potential outcomes under each
treatment. The propensity scores were estimated by a linear logistic regression with H1 and H2 as
predictors. The true optimal value in these two settings are 1.34 and 2.52, respectively. All three
methods deteriorate with the introduction of unmeasured confounders in both S1 and S2. In S1,
Q-learning outperforms the other two methods. In S2, M-learning provides satisfactory results: the
value function is close to the true optimal and has a high accuracy of identifying optimal treatment.
In comparison, the other two methods performs much worse even with a large sample size.
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A.2 Additional Figures of Simulations and Real Data Analyses
Below is a brief description of each figure in Appendix A.
Figure A.1: Descriptive analysis of patterns of HbA1c measurement;
Figure A.2: Additional simulation results: value comparison of four methods with propensity
scores correctly specified (top panel) and misspecified (bottom panel);
Figure A.3: Additional simulation results: value comparison of four methods in the presence of
unmeasured confounders.
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(b) Metformin + Insulin














(c) Metformin + Glyburide














(d) Metformin + Glipizide
Figure A.1: HbA1c values and measurement intensity (Time 0: first stage treatment prescription)
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 Q-Learning 
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1.62 1.67 1.77 1.76 1.7 1.79 2.0 1.99 1.72 1.87 2.11 2.1 1.74 1.93 2.16 2.14
 Q-Learning 
 AO-Learning 
 M-Learning (g(x) = x)  
 M-Learning (g(x) = 1)  
(d) Setting S2, propensity score model misspecified
Figure A.2: Value comparison of four methods with propensity scores correctly specified (top panel) and
misspecified (bottom panel). The numbers at the top of each subfigure are mean values.
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1.48 1.74 1.88 1.87 1.52 1.86 2.09 2.07 1.42 1.87 2.18 2.16 1.4 1.93 2.22 2.21
 Q-Learning 
 AO-Learning 
 M-Learning (g(x) = x)  
 M-Learning (g(x) = 1)  
(b) Setting S4: unmeasured confounders present
Figure A.3: Value comparison of four methods in the presence of unmeasured confounders. The numbers
at the top of each subfigure are mean values.
APPENDIX B. APPENDICES TO CHAPTER 3 118
Appendix B
Appendices to Chapter 3
B.1 Additional Simulation Results for Q-learning
In this section, we present simulation results for Q-learning (Figure B.1). In scenario (i), using
RCT feature variables alone achieves a value close to 1.28. Strategy S2 of directly adding super
features reduces variability of value function for Q-learning, but does not improve its mean. This
is consistent with our justification in Case I in Chapter 3 Section 2.3. In scenario (ii) with a latent
tailoring variable, adding super features directly to Q-learning slightly improves the original value
function of 0.98 when without H. If using linear regression instead of random forest regression for
Q-learning (bottom panel), we observe that both stratification methods much improve results with
larger values and smaller variability, which is consistent with our justification in Case II in Chapter
3 Section 2.3.
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Restricted testing population
S1: Excluding EHR-derived features 
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General testing population 
Restricted testing population
S1: Excluding EHR-derived features 
S2: Including Two EHR-derived features 
S3: Stratified by Benefit 
S4: Stratified by Probability 
(d) Scenario (ii), linear regression
Figure B.1: Simulation Comparisons for Q-learning (evaluated on independent testing sets gen-
erated from general or restricted population; scenario (i) has no latent tailoring variables while
scenario (ii) has a latent tailoring variable not used in learning)
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B.2 Additional Simulation Results for Unmeasured Confounder
In this section, we present additional simulation results for kernel M-learning under presence of
unmeasured confounders in three settings. In these settings, the outcome model is same as that in
the main text and was evaluated on the general population. In setting 1 and setting 2, the true
treatment assignment model was specified as P (A = 1|X) = expit(1 + 2X1 + X2 + 0.5X3) and
P (A = 1|X) = expit(1 + 2X1 + X2 + 2X3) respectively, where X3 is an unmeasured confounder.
In setting 3, the true treatment assignment model was specified as P (A = 1|X) = expit(1 + 2X1 +
2X2+X3+R
(1)−R(−1)) where X2 is an unmeasured confounder that determines potential outcomes
R(1), R(−1) under each treatment and treatment assignment. In addition to the four strategies S1-
S4, we include S5 which represents stratification by both super features H1 and H2 in the first two
settings. Due to relative small sample size for one of the four strata, in setting 3 the result for
stratifying by both super features is not available.
The results are summarized in Table A3. The proportion of patients receiving the optimal
treatment is defined as “success rate”. The value function of proposed approach with stratification
remains to be better than not using any EHR-derived features. In S3 and S4, “success rate” is
higher than S1. However, the performance decreases when the strength of confounding increases in
setting 3 compared to setting 1 and 2. Stratification by both H1 and H2 leads to best performance
in setting 1 and 2 with highest value function and “success rate”.
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Table B.1: Additional Results for Value Function and Success Rate
Setting 1 Setting 2 Setting 3
Strategy∗ Value Success Rate Value Success Rate Value Success Rate
S1 0.75 (0.16) 0.66 (0.04) 0.75 (0.16) 0.66 (0.04) 0.45 (0.32) 0.62 (0.07)
S2 0.71 (0.15) 0.66 (0.04) 0.72 (0.15) 0.66 (0.03) 0.81 (0.16) 0.67 (0.04)
S3 0.84 (0.13) 0.68 (0.03) 0.77 (0.14) 0.66 (0.05) 0.75 (0.14) 0.65 (0.03)
S4 0.83 (0.14) 0.73 (0.04) 0.83 (0.14) 0.73 (0.03) 0.79 (0.13) 0.68 (0.02)
S5 0.90 (0.12) 0.72 (0.03) 0.96 (0.07) 0.74 (0.02) NA NA
∗: S1: RCT features only; S2: Augment RCT feature set by two EHR data-derived super features H1, H2; S3: Include
H1 in the feature set and stratify by H2; S4: Include H2 in the feature set and stratify by H1; S5: Stratify by H1
and H2.
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2. Topic Model Features







1. Raw Count 




Figure C.1: EHR Data Preprocessing Chart for Different Domains
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C.2 Measurement Pattern and Medication Figures

























Figure C.2: Sample Patients Lab Tests Spikeplot
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Figure C.3: Sample Patients Medications Spikeplot


















































Figure C.5: Sample Patients HbA1c Spikeplot
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(b) Metformin + Insulin
1 2 3 4 5 6 7





















(c) Metformin + Glyburide
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(d) Metformin + Glipizide
Figure C.6: Longitudinal Measurement Pattern (Gap Days) of HbA1c vs. Glucose
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(b) Metformin + Insulin















(c) Metformin + Glucose















(d) Metformin + Glipizide
Figure C.7: HbA1c Measurement Pattern vs. Medication (Gap Days)
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C.3 Learned Topics Visualization from LDA Model
Figure C.8: Visualization of Co-medication Topic #3 and Their Most Relevant Terms
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Figure C.9: Visualization of Condition Topic #2 and Their Most Relevant Terms
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Figure C.10: Visualization of Condition Topic #5 and Their Most Relevant Terms
